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Abstract
Robert J. Mosley
BIOMIMETIC STRATEGIES TO CONTROL THERAPEUTIC RELEASE FROM
NOVEL DNA NANOPARTICLES
2021 - 2022
Mark E. Byrne, Ph.D.
Doctor of Philosophy in Biomedical Engineering
The inherent chemical, mechanical, and structural properties of nucleic acids
make them ideal candidates for the formulation of tunable, personalized drug
nanocarriers. However, none so far have exploited these properties for the controlled
release of therapeutic drugs. In this dissertation, a biomimetic approach to controlling
drug release is exhibited by specifically manipulating the architecture of novel, DNA
nanoparticles to take advantage of drug binding mechanisms of action. Rationally
designed DNA strands were immobilized on gold surfaces via a terminal thiol
modification. Immobilized monomers can be manipulated to form distinct monolayer
architectures including flat, folded, coiled, or stretched structures. Increasing the rate of
folding is shown to restrict the diffusion of a surface-bound drug while upright
architectures released drug at a 2 - 10 fold rate, depending on sequence length - using this
strategy an over four-week release of dexamethasone was achieved. Furthermore, the
release of an intercalating drug is controlled by exploiting sequence-specific affinities of
the drug toward DNA. Here, using a high-affinity sequence and increasing the strand
length a near zero-order release of daunomycin was achieved for up to 12 days. With this
work, it is shown for the first time that the mechanisms of drug binding to nucleic acids
can be utilized to produce highly controlled drug release from gold-core nucleic acid
nanoparticles. These results will have a profound impact on the future design of novel,
therapeutic nanocarriers.
v
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Chapter 1
Introduction
1.1 Background
Cancer is a leading cause of death and a growing public health crisis worldwide.
In 2020 alone it was associated with over 13 million new diagnoses and more than 6
million deaths.1 Although referred to as a "disease", cancer is a general term describing a
class of diseases identified by abnormal cell proliferation generally identified by
uncontrolled cell proliferation triggered by the accumulation of genetic mutations.
Cancers are distinguished by the site of origin: the top three cancers by diagnoses are
breast, lung, and colorectal, and the top three by mortality are lung, colorectal, and liver.
In low and middle-income countries, a significant fraction of cancers are caused by
pathogens that are implicated in the development of cancer.1 In all other populations,
almost half of all cancers are caused by risk factors like tobacco and alcohol
consumption, unhealthy diet, physical inactivity, and exposure to pollutants.2 For cancers
that have a good surveillance method, can be detected early, or are still organ confined,
effective treatment and improved prognosis is more likely. However, late diagnosis or
metastasized cancers still present a high risk of mortality, and certain types (e.g.
pancreatic, liver, small-cell lung, and uterine corpus) remain significantly challenging to
treat effectively.
In the United States, cancer is the second leading cause of death (21% of all
mortality) and the leading cause of death among women aged 40-79 years and men aged
60-79 years. The chances of being diagnosed are 40.2% for men and 38.5% for women
over a lifetime. Breast, prostate, lung, and colorectal cancer accounting for about half of
1

all diagnoses. In 2022 there will be almost two million new cancer cases, about 5,000
each day, and over 600,000 deaths, about 1,700 per day, in the US alone. The total
economic burden is expected to reach over $246 billion by 2030 with annual average
medical costs for patients exceeding $42K, $5K, and $105K in the initial, continuing, and
end-of-life phase of care, respectively. The burden will be exacerbated in subsequent
years due to the substantial reduction in routine cancer screenings caused by
overwhelmed healthcare facilities during the COVID-19 pandemic.3,4
Modalities in cancer therapy have gone through a series of phases over the past
century (Figure 1.1). Although cancer has been known to practitioners of medicine for
millennia, it was not until the late 19th century that the idea of chemically treating the
disease, or chemotherapy, was proposed by Dr. Paul Ehrlich. It was initially his research
on the affinity of small molecules that led to his hypothesis of molecularly targeted
compounds, or, in his own words, “wir müssen chemisch zielen lernen” (“we have to
learn how to aim chemically”).5 In the following years George Clowes successfully
transplanted tumors in rodents leading to a phase of developing relevant clinical models
which resulted in the Sarcoma 37 (S37), Sarcoma 180 (S180), Walker 256, and Ehrlich's
ascites tumor models.6 This phase culminated in Murray Shear's 1935 program for cancer
drug screening, which screened over 3,000 compounds but was ultimately dropped due to
a lack of understanding of cancer and the ethical issues of testing toxic compounds in
humans.7
The fervent search for chemotherapeutics continued after World War II stemming
from the observation of depleted lymph nodes and bone marrow in soldiers exposed to
mustard gas; this resulted in the discovery of a number of alkylating agents and folate
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analogs used with little success throughout the 1950s. It was not until the 1960s, assisted
by the discovery of the double helix by Watson and Crick, that the idea of DNA functionaffecting compounds as anticancer agents emerged.8 The first example of a cured cancer
was Hodgkin's lymphoma, in 1970, via aggressive administration of a combination of
chemotherapeutics.9
Improved understanding of cancer-specific genetics and signal transduction
pathways, along with the production of the first monoclonal antibodies (mAbs) in 1975,10
led to the next phase of specific targeting of cancer hallmarks led by the treatment of
chronic myelocytic leukemia via Bcr-Abl tyrosine kinase inhibitor in 1996.11 In the
following decade the immune therapies, including immune checkpoint inhibitors and
modified T cells expressing chimeric antigen receptors (CAR T-cell therapy), began to
emerge.12,13 The suboptimal clinical efficacy of these new targeted therapies, and the
previous success of combination therapies, resulted in a shift to applied nanotechnology
to produce targeted drug payload carriers, or nanocarriers. The beginning of the
nanocarrier phase is marked by the FDA approval of Doxil in 1995.14 The nanocarrier
strategy is highly emphasized in the current day, fueled by a continued investigation of
patient and disease-specific cancer hallmarks leading the field to the precipice of truly
personalized therapeutics.15 Unfortunately, there are still challenges to overcome.
1.2 Motivation
The difficulty in treating cancer is due to the unique properties of the disease itself
(Figure 1.2). The major characteristics of cancer are uncontrolled growth and
proliferative signaling, genetic instability and mutation, stimulation of angiogenesis,
evasion from growth suppressors and the immune system, inflammation, and the
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promotion of invasion and metastasis (Table 1.1). The so-called "tumor
microenvironment" accounts for all stages of cancer progression including tumorigenesis,
growth, proliferation, and metastasis.16 Due to the difficulties in specifically targeting
cancer cells, the search for the proverbial "magic bullet" has so far failed.5 An emerging
paradigm in cancer treatment revolves around the manipulation of materials at the nanoscale to produce multifunctional, specifically targeted therapeutic agents. Nanoparticles
have been observed passively accumulating at tumor sites due to the upregulation of
vascularization in tumors via the enhanced permeability and retention (EPR) effect.
Furthermore, nanotechnology provides an outstanding suite of techniques and strategies
for tuning materials for physical, chemical, and functional properties useful in medicine.
In vitro, this has led to the formulation of highly functional, stimuli-responsive, "smart"
nanomedicines designed with regard to specific cancer hallmarks or microenvironmental
triggers. Of the multitude of nanomaterials in use, nucleic acids (NAs) have emerged as a
very promising component in the construction of next-generation cancer therapeutics.17
The unique information-carrying properties imbued by the sequence-specific base pairs,
directed layer-by-layer assembly, stimuli responsiveness, biocompatibility, and drug
loading capacity are all advantages of NAs which make them attractive for constructing
cancer nanomedicines. However, controlled and extended release constitutes a great
challenge at the nanoscale. A strategy that takes advantage of the mechanisms of action
of drug binding to nucleic acids has yet to be exhibited and would significantly improve
drug release kinetics and nanocarrier design. Therefore, the main goal of the research
herein is to engineer novel nucleic acid nanoparticles and develop methods by which the
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release of chemotherapeutics can be controlled via a biomimetic approach to drug loading
and release.
1.3 Objective
A tunable, tailorable, platform-based delivery of therapeutic molecules would
revolutionize both diagnostics and therapeutics for cancer treatment.18 This work,
therefore, is motivated by the desire to develop such a platform with emphasis placed on
NAs as the functional component. The specific objectives involve the discovery and
development of novel methods of controlling the release of chemotherapeutic drugs
bound non-covalently to the surface of nucleic acid-based, biohybrid nanoparticles via
biomimetic design strategies (Figure 1.3). Specifically, biomimetic strategies involve
manipulation of the mechanical and structural properties of DNA and exploiting drug
binding mechanisms of action to control release. Chapter 2 will describe the rational
design of drug nanocarriers and the influence of key physical properties on their in vivo
fate with emphasis on NA nanocarriers. Chapter 3 introduces a dendritic DNA
nanocarrier loaded with cytotoxic doxorubicin engineered to target a specific
subpopulation of cells via conjugation of a monoclonal antibody; an elegant and highthroughput cell culture model was designed and showcased to compare a novel controlled
release mechanism to a bolus injection in dynamic flow environments. Chapter 4
introduces DNA-gold conjugates as a platform for building advanced nanocarriers, with
the controlled manipulation of DNA layers on both planar gold surfaces and gold
nanoparticles highlighted. Chapter 5 utilizes the manipulation of DNA films on gold to
control the release of a surface bound chemotherapeutic, dexamethasone. Here,
controlled release is achieved via modulation of DNA nanoarchitecture correlated to the
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degree of folding about the gold core. Chapter 6 subsequently showcases the controlled
release of the intercalating chemotherapeutic daunomycin from DNA films on gold. In
this case, control is achieved via modulation of DNA sequence and length, taking
advantage of the mechanism of binding of daunomycin to DNA. Comparisons of release
profiles from planar gold films and gold nanoparticles are also shown. Chapter 7 provides
a summary of conclusions, highlighting major results and significant contributions to the
field of drug delivery and nanocarrier design.

6

Figure 1.1. A brief history of chemotherapy. The history of chemotherapy starts with Dr.
Paul Ehrlich who posited the idea of chemically targeting cancer in the early 1900s, thus
inventing the concept of chemotherapeutics. The next phase involved the rapid
development of relevant clinical models for different cancer types. The rational design
and discovery of chemotherapeutic drugs was accelerated by novel effects observed due
to mustard gas, leading to the focus on alkylating agents as anticancer drugs. Throughout
the mid-1900s, spurred by the discovery of the DNA double helix, a large number of
novel drugs were synthesized to target DNA replication; this phase culminated in the first
cured cancer via combination therapy in 1970. For the rest of the century, targeted
therapies began to emerge based on specific oncogenes and proteins, with the very late
years of the 1900s showcasing the utility of drug nanocarriers with the approval of Doxil.
Over the past few decades, an improved understanding of cancer genetics and
heterogeneity has pushed the development of highly tailorable nanocarriers for the
multiplexed delivery of chemotherapeutic drugs.

7

Figure 1.2. The tumor microenvironment. The tumor microenvironment plays a role in all
stages of cancer progression including tumorigenesis, growth, proliferation, and
metastasis. Triggered by mutations that cause unchecked multiplication and proliferation,
tumors grow rapidly at the tissue or organ of origin. Upregulated vascularization draws
nutrients from the blood stream while dysregulated gene expression helps cancer cells
evade growth suppressors and the immune system. The resultant vasculature is tortuous
and leads to inflammation, intratumoral pressure, and a buildup of metabolic waste. Over
time, tumors can metastasize and invade other tissue.
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Figure 1.3. A novel, biohybrid therapeutic nanocarrier. The main subject of this work is a
novel, biohybrid nanocarrier formed via conjugated of a 5' thiol-terminated
oligonucleotide to the surface of a 15 nm gold nanoparticle in a radially arranged
orientation. Various drugs can be bound non-covalently to the surface of the particle by
adhering them to the gold surface or by arranging them within the nucleic acid
monolayer. The mechanisms of drug binding and manipulation of nucleic acid structures
can be used to control drug release.

9

Table 1.1
Difficulties in Treating Cancer
Cancer property

Result

Uncontrolled growth

•
•
•

Accumulation of mutation
Aberrant signaling
Promotion of invasion

Proliferative signaling

•
•
•

Tumor growth
Evasion of growth suppressors
Cancer progression

Genetic instability and
mutation

•
•

Genetic heterogeneity
Acquired resistance to treatment

Stimulation of angiogenesis

•
•

Increased nutrient uptake
Accumulation of metabolic waste

Evasion of growth suppressors
and immune system

•
•

Unchecked proliferation
Resistant to body's natural defenses

Inflammation

•
•
•

Intratumoral pressure
Restricts delivery of therapeutics
Causes further tissue damage

Promotion of invasion and
metastasis

•
•
•

Cancer spread throughout the body
Affects unrelated tissue
Difficult to diagnose/treat

10

Chapter 2
Rational Design of Nanocarriers for Improved Drug Delivery
2.1 Introduction
Nanomedicine is one of the most promising drivers of next-generation therapeutic
strategies for the management of pressing diseases. The unique optical, magnetic,
electronic, and structural characteristics that emerge at the nanoscale have resulted in the
rational design of novel formulations tailored for urgent medical needs including sensing
and imaging, drug delivery, tissue engineering, and gene therapy.19–21 Since the
introduction of the term “nanomedicine” over 30 years ago, research on the topic has
expanded significantly with more than 50 approved formulations, hundreds of ongoing
clinical trials, and a 1000X increase in peer-reviewed manuscripts.22–24 Most affected has
been cancer treatment due to the development of a variety therapeutic agents designed
with molecular precision for the treatment of specific cancer genotypes.25 Additionally,
advances in diagnostics and treatment of, e.g., reproductive diseases,26 Alzheimer’s,27
infectious disease,28 cardiovascular disease,29 viral diseases,30 chronic inflammation,31
and neurodegenerative diseases32 have showcased the utility of nanomedicine in a broad
range of diseases. At its core the advantage of nanomedicine lies in the tunability of
nanomaterials which allow for highly versatile and multifunctional therapeutic agents,
often referred to as personalized medicines (Figure 2.1).33 In particular, the inclusion of
biomolecules has had an enormous impact on the rational design of nanomedicines. The
chemical complexity and high molecular weight of biomolecules imbue intricate
architectures and unique mechanical properties to biohybrid materials.34,35 They are
generally highly functional and exhibit dynamic and stimuli-triggered responsiveness, i.e.
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“smart” materials.36–40 Designs inspired by or mimicking the complexity of biological
tissue have increased precision and personalization in both diagnostics and therapeutics.41
Unfortunately, the unpredictable efficacy of nanomedicines in human patients
related mainly to in vivo pharmacokinetics, tissue distribution, immunological responses,
and penetration and accumulation at the target site have limited the clinical success of
nanomedicines.42–44 Biological barriers such as fluid dynamics within the blood,
opsonization and recognition by the mononuclear phagocyte system, extravasation to the
disease site, and intracellular compartmentalization all determine the in vivo fate of
nanomedicines and thus must be considered in the design of novel formulations.45
Attempts at designing biomimetic materials meant to mimic the dynamic properties of
biological tissue have revealed the lack of understanding of biomolecular physics at the
nanoscale.46,47 Thus, a new paradigm of bio-inspired materials has focused instead on
exploiting the modulatory nature of biomolecules as building blocks of nanoparticle
therapeutic delivery vehicles, or nanocarriers, instead of using them strictly for their
biological mechanisms of action. In terms of therapeutic delivery, nanocarriers maintain
advantages over other nanomedicines including diversity of payload, high drug-totargeting-ligand ratio, multivalency, and controlled drug release.48 Furthermore, utilizing
bio-inspired materials in this way allows for more simplified, holistic design principles
that can dictate nanocarrier formulation for improved therapeutic outcomes.49–51
In this chapter, a summary of the physical properties of nanocarriers and their
effect on in vivo fate will be discussed. These properties include the size, shape,
mechanical properties, and surface properties of nanocarriers. These properties are then
discussed specifically in the administration of nucleic acid-based nanocarriers due to their
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unique applicability as controllable, self-assembling, and highly functional building
blocks for nanomedicines. Finally, the controlled release of therapeutics from nucleic
acid-based nanocarriers will be discussed.
2.2 The Influence of Physical Properties on Nanomedicine Fate In Vivo
The most important factor in the design of nanomedicines is their interactions
with biomacromolecules. Thus, many researchers take the approach of functionality
through synthesis whereby specific chemical units are incorporated onto nanocarrier
surfaces to exploit their inherent biological mechanisms of interaction.52 For example,
outfitting surfaces with small molecules, polymers, biomolecules, etc., can impart
specific biomedical functionalities including immune recognition, cell internalization,
molecular targeting, drug loading, biosensing, and biological stealth. The chemical
tailorability of nanomaterials presents a seemingly limitless collection of possible surface
modulations that has accelerated the development of novel nanomedicines and
nanocarriers; however, the excitement has not led to a proportional increase in clinical
translation.53
The myopic focus on functionality and the lack of clinical success has revealed an
immense ignorance of the essential physical parameters that drive the biological
interactions of nanomaterials. In this section, a general overview of these parameters specifically, size, shape, mechanical properties, and surface properties - and their effect
on the in vivo fate of nanocarriers will be presented and discussed.
2.2.1 Size
Nanoparticles, by nature of their dimensions, are able to freely circulate through
vasculature and are readily cleared from tissue.54,55 However, physiological barriers

13

imposed by organs involved in filtration, recognition, and removal of foreign material particularly the kidneys, liver, and spleen - severely limit therapeutic delivery and induce
prohibitive side effects via accumulation of toxins in these organs. Particle size plays an
important role in the ability of a nanocarrier to maneuver through these physiological
barriers (Figure 2.2).
Renal filtration is the process by which the kidneys filter waste products out of the
blood and excrete them in urine. This process will remove most particles of < 15 nm in
diameter and all particles of 6 nm or smaller.56 Thus, 15 nm is the lower limit for a
circulating nanocarrier. Increasing particle size, however, correlates to an increase in
phagocytosis and the accumulation of particles in the liver; this occurs in the range of 15
- 200 nm.57,58 This process occurs largely via resident macrophages known as Kupffer
cells,59 although particles on the lower end of this range are also removed via receptors
on liver sinusoidal endothelial cells and hepatic stellate cells.60 It is also driven by
adhesion of circulating opsonin proteins which allow for recognition of foreign materials.
The role of the spleen in nanocarrier sequestration is less broadly elucidated. Marginal
zone macrophages within the spleen were observed to selectively internalize
nanoparticles with sizes between 100 - 200 nm.61 Larger particles are subsequently
filtered out and retained in the red pulp of the spleen where they become internalized by
red pulp macrophages; sequestration in the red pulp is maximized with particles larger
than 400 nm in diameter.61
The size of a nanocarrier also affects the ability to marginate to endothelial tissue.
Margination is the movement of nanocarriers under dynamic fluid flow from the center
toward the walls of a channel. For most drug delivery applications, margination is
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imperative as it encourages attachment and diffusion of nanocarriers through the
endothelium and into disease sites. It was previously found that particles of less than 100
nm were found to interact with the endothelium more often compared to larger
particles.62 This phenomena is likely due a result of lower drag force and larger contact
area of smaller particles.63 In tumors, margination is less important as the EPR effect
encourages passive accumulation at the target site. The intervascular pores in tumors,
which do not exist in most healthy tissue, are between 100-780 nm in diameter and thus a
wide range of particle sizes can naturally accumulate in these spaces.64 However, larger
particles tend to induce higher background accumulation in healthy tissue in spite of the
EPR effect.65 Therefore, designing nanocarriers with diameters between 15 - 100 nm
would provide the most efficient tumor targeting without accumulation in healthy organs
or tissue.
2.2.2 Shape
Precision in nanotechnology has resulted in the synthesis of a wide variety of
nanoparticle shapes, including spheres, rods, discs, stars and polyhedra. Only recently
was shape investigated as a driver of biological interactions (Figure 2.3). One of the most
influential parameters regarding nanoparticle shape is the surface curvature. On the
nanoscale, the high surface area to volume ratio of particles results in significant
curvature compared to more macro-sized curved particles. This high curvature can
substantially alter the orientation of surface bound ligands, such as conjugated antibodies,
which significantly affects binding specificity and avidity of targeted nanocarriers.66,67
Additionally, surface curvature can affect macrophage uptake. Highly curved surfaces
lower the thermodynamic barrier to protein adsorption and thus are recognized and
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phagocytosed by macrophages at a higher rate.68,69 They also show increased
accumulation in the liver compared to disc-shaped or hexagonal nanoparticles.57,63,68
Indeed, the local surface curvature affects the rate of phagocytosis by directly influencing
the actin structure of macrophages; spherical particles that require a gradual expansion of
actin ring are phagocytosed more efficiently compared to particles that require a high
degree of macrophage spread along the surface.70
Similar to surface curvature, the aspect ratio of nanocarriers plays a significant
role in influencing biological interactions. Ellipsoidal or rod-shaped nanoparticles are
phagocytosed at a much lower rate than spherical nanoparticles, which is related to the
lower surface curvature along the long axis.71,72 Indeed, this observation is less
pronounced in shorter rod-shaped particles which tend to accumulate more frequently
within the liver.73 Regarding tissue penetration, the tumbling motion of rod-shaped
nanoparticles in the blood stream results in increased contact and adherence to
endothelial tissue.74 Furthermore, compared to spherical particles they show increased
transport across intestinal endothelium, blood-brain-barrier, accumulation in tumors, and
passive diffusion to the nucleus.75–78 Aspect ratio also affects biological function and
cytotoxicity. Increasing particle aspect ratio has been observed to influence cellular
functions such as proliferation, apoptosis, cytoskeleton formation, adhesion and
migration.79 Furthermore, higher aspect ratio, "needle-shaped" particles were found to
induce a significant amount of cytotoxicity due to lysosomal disruption.80 Particles with
very high aspect ratios are known as filamentous nanoparticles. These have shown the
excellent ability to remain in circulation up to ten times longer than spherical
nanoparticles and are readily taken up by endothelial tissue.81,82
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2.2.3 Mechanical Properties
The mechanical properties of nanocarriers have only recently been recognized as
a mediator of effective drug delivery (Figure 2.4).83 As such, the effects of mechanical
properties on drug delivery are not fully understood. Soft particles exhibit significantly
improved circulation times compared to rigid particles.84 The deformability of soft
particles increases their ability to pass through biological filters (e.g., in the spleen)
leading to improved circulation time and reduced uptake by the immune system;
additionally, the deformability of a particle significantly reduces the rate of
phagocytosis.70,85,86 However, this flexibility also increases interactions with opsonin
proteins which can increase the rate of macrophage uptake.87
Opsonization is significantly reduced by increasing the rigidity of a
nanocarrier.87,88 However, the flow dynamics of hard particles result in a higher chance of
marginating and encountering macrophages within the liver.89 Surface-bound ligands are
able to interact with the biological environment more readily on the surface of rigid
nanoparticles. In the case of ligand targeting, this leads to improved receptor mediated
uptake; however, in cases such as Fc-receptor-mediated phagocytosis, uptake by
macrophages is also increased for rigid particles.90,91
Overall, conclusions about the optimum mechanical properties of nanocarriers are
difficult to draw. At times reports may contradict about the biological effect of varying
mechanical properties. For example, both increasing and decreasing the moduli of
nanoparticles have shown advantages regarding targeting and tissue penetration.91,92 As
such, mechanical properties must be optimized on a case-by-case basis in order to tune
the nanocarrier for targeting and transport through specific physiological environments.93
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2.2.4 Surface Properties
Chemical properties such as charge and hydrophobicity are understood to affect
protein adhesion, transport through tissue, interactions with cells, transcytosis,
phagocytosis, and particle biodegradation.58,94–98 However, a less understood mediator of
nanocarrier fate is in the nanoarchitectures of the functional ligands bound to a particle
surface. As discussed above, functionalization via conjugation of ligands is the most
popular method of formulating nanocarriers but has not translated to significant clinical
success. Therefore, this section will discuss physical considerations for the functionalized
surface layer in the context of nanocarrier interactions with the biological environment.
Functional groups grafted to the surface of nanocarriers dictate many of the
interactions the nanocarrier has with biological barriers. These interactions are not always
simply understood. For example, certain surfactants are able to mimic lipoprotein
particles to encourage transport across the blood-brain-barrier, while others do not elute
the same kind of uptake.99 The density of functional ligand, specifically those meant for
molecular targeting, is also essential for dictating particle-cell interactions. Increasing
ligand density results in stronger and faster bond formation with its target, although too
high of a density can lead to reduced interactions.74,100 Thus, it is not only density but the
local nanoarchitecture that dictates the in vivo fate. Indeed, nanoparticle tropism for
neutrophils was seen to be significantly dependent on the supramolecular arrangement of
proteins rather than size, shape or charge.101 In experiments using self-assembled
monolayers of oligo(ethylene glycol) and polyethylene glycol, polymers commonly
utilized to increase solubility and reduce biofouling, it was found that resistance to

18

protein adsorption and cell uptake were more dependent on the spatial configurational
freedom of the polymer chains than the density of the polymer on the surface.102,103
The effect of polymer architecture also extends to the formulation methods of the
nanocarrier. It was shown that nanocarriers with grafted PEG-PLA coatings had
significantly reduced protein binding and macrophage uptake compared to multiblock
PLA-PEG-PLA polymer despite the relatively lower PEG content.104 Verma et al.
constructed nanoparticle "isomers" using 11-mercapto-1-undecanesulphonate 1octanethiol in either a striated or randomly distributed conformation. They confirmed that
the striated polymer coating allowed for penetration of the plasma of the plasma
membrane without disruption where the randomly distributed coating restricted
nanoparticles to the endosomes.105 Here, therefore, the biomimetic approach is key to
tuning the biological interactions of a nanocarrier. For example, nanoporous silicon
particles showed excellent "cell-like" properties after being coated with membranes
purified from leukocytes.106
2.3 Nucleic Acid Nanocarriers
Nucleic acids (NAs) are commonly known as the essential holders of genetic
information for the perpetuation of all life. They are extremely versatile building blocks
in the construction of complex networks and nanostructures. NAs are biological polymers
consisting of helically stacked purine and pyrimidine bases that are connected to a sugarphosphate backbone and form the well-known double helix structure. At the turn of the
21st century, advances in NA chemistry provided the opportunity for large-scale,
inexpensive production of synthetic NAs.107 Around the same time, reports of the SELEX
method for discovering molecularly targeted NAs increased the interest in utilizing NAs
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in the construction of multifunctional theranostic tools.108–111 The specificity of base
pairing along with conjugation chemistry allowed self-assembly and layer-by-layer
deposition strategies for facile synthesis of highly modular and versatile materials to act
as therapeutics (Figure 2.5).112 Over the last 30 years, NA therapies approved by the FDA
have included antisense oligonucleotides, siRNAs, one aptamer (Pegaptanib), and two
mRNA-based vaccines for COVID-19 granted emergency use authorization by FDA.113
Furthermore, there are currently over one hundred ongoing clinical trials involving NA
therapeutics.114
Effective targeted or systemic delivery of NA therapies is limited mainly due to
the physiochemical properties of NAs themselves. As large hydrophilic molecules they
are unable to penetrate cell membranes. Additionally, their susceptibility to enzymatic
activity causes them to be rapidly degraded in the bloodstream and in the cytoplasm. As a
result, most NA therapies require chemical modification of oligonucleotides or
administration alongside active molecular enhancers in order to remain stable in vivo for
delivery to disease sites.115,116 More contemporary strategies have placed high emphasis
on designing nanocarriers for efficient delivery of NAs, mostly involving methods of
encapsulating or protecting the cargo instead of utilizing it as a functional unit within the
nanocarrier itself.117,118 This strategy can prove effective but it significantly limits the
functionality of NAs. For example, engineered NAs with specific sequence sites related
to targeting, immunomodulation, structural stability, and drug loading can be
incorporated into a single, modular nanocarrier.119 With each facet of this nanocarrier
contained within a single, molecular component, the physical properties of the
nanocarrier can then be tuned for a specific purpose. The physical properties discussed in
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Section 2.2 will be again discussed in the following section with specific focus on NA
nanoparticles.
2.4 Rational Design of Nucleic Acid Nanocarriers
NAs administered systemically have three major barriers to overcome: stability
and degradation in physiological media, tissue localization and penetration to the target
site, and unwanted activation of the immune system. Due to the molecular precision and
variety of nanostructures possible via NA engineering, there are multiple emerging
strategies that allow tunability regarding these three barriers. These strategies are closely
related to the physical parameters discussed in Section 2.2. Thus, this section will focus
on rational design strategies for tailoring the physical properties of NA nanocarriers for
improved performance in biological systems. Specifically, the spherical nucleic acid
(SNA) nanocarrier - nanoparticles with radially oriented oligonucleotides - will be
highlighted.
2.4.1 Stability and Degradation
Complex NA nanostructures are often unstable in physiological media. This is
due to the need for a sufficient concentration of cations to allow for dense NA packing
which is unsuitable in low ionic buffers. However, rational nanostructural design can be
used in biological applications.120 By controlling the density of DNA helices in
nanostructures, stability in physiological buffers can be achieved and has led to extremely
stable DNA nanostructures spanning a wide range of complex shapes.121 Supramolecular
DNA nanostructures, such as "chain-armor" DNA catenanes formed via azide modified
copper-catalyzed azide–alkyne cycloaddition (CuAAC) click chemistry, have also
exhibited excellent stability.122 For example, this structure was found to be stable up to
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95oC and after ethanol precipitation. Additionally, it was resistant to nuclease
degradation.122 Cationic polymer coatings are commonly utilized as protective agents
against degradation, but often this leads to unanticipated changes in particle size, shape,
and cell uptake.123 One solution has been the complexation of copolymers with NA
structures. Poly(ethylene glycol)−poly(l-lysine) (PEG−PLL) block copolymer conferred
increased thermal stability to plasmid DNA and reduced the activity of DNase I.124 The
copolymer also restricted DNA aggregation compared to PLL homopolymer due to the
segregation of DNA into the PEG core. Additionally, tubular DNA nanostructures were
observed to aggregated when coated with oligolysines but not when coated with an
oligolysine-PEG copolymer. This copolymer coating allowed the DNA structure to
survive in acidic endosomal compartments and exhibited an increase in bioavailability in
a mouse model.125 Furthermore, mixed polymer coatings or encapsulations can be
formulated to protect NA nanostructures, such as PEGylated lipid bilayers, which protect
the nanostructure against nuclease digestion and improved bioavailability to a significant
degree.126 In another example, poly(2-dimethylaminoethyl methacrylate) poly(ethylene
glycol) (PDMAEMA-PEG) copolymer was complexed with tubular DNA nanostructures.
Not only were the resulting complexes stable in physiological media, by tuning the
copolymer coverage they were able to control the catalytic activity of encapsulated
enzyme.127
SNAs provide a unique architecture for improving NA stability in vivo. Since the
oligonucleotides are not conjugated via base pairing, and due to high surface curvature at
the nanoscale reducing intermolecular repulsion, stability in physiological salt
concentrations is maintained. Furthermore, with the multivalent and cooperative
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hybridization to SNA surfaces, melting temperatures are increased and sharp melting
curves have been observed using SNAs.128 These structures also reduce enzymatic
degradation. The steric hindrance induced by dense oligonucleotide packing can inhibit
enzyme binding; furthermore, even bound enzymes are restricted from catalyzing
hydrolysis due to the local surface charge and salt concentration within the NA shelllayer.129,130
2.4.2 Tissue Localization
Targeted, tissue-specific delivery is essential for nanocarriers carrying highly
cytotoxic chemotherapeutic drugs. For NA nanocarriers, conjugation of a targeting ligand
can be done via complementary base pairing with either aptamers or other
oligonucleotide-functionalized moieties. However, considerations of ligand density,
spatial arrangement, and orientation are imperative as they can directly determine particle
affinity and avidity toward the target.131 Furthermore, encapsulated NA nanostructures
may hinder the binding mechanism of surface-bound molecules.132 Therefore, careful
consideration of the location and orientation of targeting ligands must be taken. NA
nanocarriers can also take advantage of the EPR effect for tumor targeting. Even in the
absence of a targeting ligand, increasing the size of RNA nanocarriers improved
accumulation at tumor sites.133 Indeed, the flexibility of NA nanostructures contributes
significantly to its ability to penetrate tissue, accumulate within tumors, and avoid
sequestration by the immune organs.134
Tissue targeting of SNAs is achievable via tuning of constituent components of
the particle. First off, particle size can be controlled by selecting core diameters and
oligonucleotide lengths. Radially oriented NA layers also retain a significant amount of
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flexibility allowing for deformability and more efficient penetration of tissue layers.135
Furthermore, SNAs are capable of binding multiple targeting probes with higher binding
constants for complementary strands compared to free NAs.136 In fact, the shape of SNAs
improve the display of conjugated targeting ligands and increase binding avidity.67 SNAs
are also profoundly capable of being taken up by cells and have shown to rapidly
accumulate in over 50 different cell lines without the need for transfection reagents.137
The mechanism of internalization is due to weak, non-specific protein binding on the
SNA surface activating scavenger receptors and leading to internalization138; this
mechanism is also highly dependent on the density and architecture (i.e., radial
orientation) of the NA layer.139 This allows for SNA transport across difficult
physiological barriers such as the skin and the blood-brain-barrier.140,141 Indeed, even for
cation coated SNAs the shell orientation remains capable of inducing cellular uptake.142
2.4.3 Immunogenicity
The recognition of foreign NAs involves the activation of the innate immune
system, specifically host pattern recognition receptors such as the toll-like receptors
(TLRs) and retinoic acid–inducible gene-I-like helicases (RLHs).143 This recognition is
highly dependent on the size, shape, and structure of the circulating NAs.144 For example,
RLH proteins retinoic acid–inducible gene-I (RIG-I) and melanoma-differentiation–
associated gene 5 (MDA5) recognized NAs depending on the oligonucleotide length and
TLR-9 activation is enhanced by curved DNA structures.143,145 Furthermore, pattern
recognition receptors can have specificity for specific helical structures, such as B-form
DNA, over others.146
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Planar NA structures are significantly more immunostimulatory compared to
chain or fiber nucleic acids.147,148 It was additionally found that specific shapes, such as
triangles, squares, or pentagons, can induce distinct immune responses with varying
magnitudes of immune stimulation.149 Cubical nucleic acid structures of both RNA and
DNA have shown to have vastly different immune stimulating properties.148 Furthermore,
the inclusion of single-stranded nucleic acids extended from vertices can induce a strong
immune response that is not observed when the vertices are unconjugated.150 It has been
observed that 3D tetrahedrons induce stronger immunostimulation compared to planar
structures driven by sequence specific extensions from vertices.150
The immune response to internalized SNAs is significantly decreased compared
to free NAs. Specifically, this is due to a restriction in the activity of enzymes responsible
for recognizing foreign NAs and was observed to be inversely dependent on the surfaces
density of oligonucleotides.151 Indeed, the display of immunostimulatory
oligonucleotides, such as the CpG motif, can be tailored on SNAs to tune the activation
of macrophages.152 This control has led to a great emphasis on using SNAs as vaccine
adjuvants. Co-delivery of antigens paired with an SNA construct showed markedly
improved immunostimulation depending on how the antigen was incorporated into the
nanoparticle.153 An SNA designed with peptides for human prostate-specific membrane
antigen (PSMA) resulted in elevated secretion of cytokines and increased cytotoxic T cell
activity in humanized mice and human peripheral blood mononuclear cells.154 More
recently, an SNA coated with the COVID-19 receptor-binding domain (RBD) subunit
and a dense shell of CpG motif oligonucleotides led to a 100% survival rate in humanized
ACE2 transgenic mice.
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2.5 Controlled Release Strategies from Nucleic Acid Nanocarriers
Although used frequently as a drug carrier, controlling the release of drugs from
NAs presents a significant challenge. This is due to the high surface area to volume ratio
at the nanoscale, which allows for excessive hydration and solvation, along with the
extremely short diffusion path for the drug to escape. However, utilizing NAs as
nanocarriers as opposed to administering them alone as therapeutics leads to improved
treatment outcomes and reduction of multidrug resistance.155 Furthermore, controlled
release is essential for therapeutics that act as circulating drug reservoirs, require passive
or active targeting, and assists in avoiding off-target accumulation and associated
toxicities.156,157 NAs, with their profound capacity for layered self-assembly and
modification, are ideal candidates for constructing controlled release nanocarriers.158
Physical triggers to alter NA structure are commonly used to control the release of
drugs. Heat denaturing of NA shell-layers can be achieved via administration of nearinfrared (NIR) light to injected, NIR absorbing gold nanoparticles (AuNPs); the specific
wavelength of light can be tuned by changing the size of the AuNP core.159 Additionally,
pH sensitive structural changes, such as induction of the i-motif for C-rich
oligonucleotides, can effectively be used as triggered drug release in low pH
environments. Dexamethasone-conjugated oligonucleotides hybridized to a DNA
nanotube via the i-motif sequence showed selective drug release under acidic pH at
37°C.160 This technique has also been used to release intercalating doxorubicin in
endosomal compartments.161 Specific recognition sequences have also been utilized to
achieve enzyme-specific degradation and drug release from NA nanoparticles.162
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Steric and electrostatic hindrance of drug diffusion can be exploited by blocking
diffusion paths with oligonucleotides, a mechanism known as DNA-gated release. Most
commonly this is done by loading drug into porous nanoparticles and arranging
oligonucleotides to block the pores. This strategy can be used effectively and reversibly
in a temperature specific manner where thermal melting and rehybridization of DNA
duplexes effectively triggers the release or entrapment of the drug payload.163 Using an
aptamer as the gate mechanism allows for triggered release of drug payloads in response
to specific antigens.164–167 This mechanism can also be exhibited on non-porous
nanoparticles. For example, we recently showed that the release of dexamethasone bound
to a AuNP surface can be slowed substantially by promoting folded, looping DNA
structures in the DNA shell layer (discussed in Chapter 5).168 Indeed, engineering
nanoparticles with these sequence specific gate mechanisms has led to the exhibition of
higher order "logic" mechanisms that are able to multivalently target specific molecular
antigens and trigger specific release of encapsulated therapeutics.169–171
Intercalating drugs are popular payload candidates for NA nanocarriers due to
their inherent ability to bind to NA sequences. However, controlled release of
intercalators presents a great challenge. Certain intercalators, such as daunomycin, are
known to have sequence-specific affinities toward NAs. Specifically, daunomycin is
known to bind with high affinity to the AGC oligonucleotide motif. We have shown that
the arrangement of this motif along an oligonucleotide conjugated to AuNPs can affect
the loading and release of daunomycin.172 More recently, by engineering AGC-motif
oligonucleotides on gold films we showed near zero order release of daunomycin
(discussed in Chapter 6). Therefore, drug release can be controlled from NA shell-layers
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via careful engineering of the sequence, size, and structure of the oligonucleotides.
2.6 Conclusions
NA nanocarriers are quickly gaining recognition as one of the most promising
nanomaterials for the formulation of next-generation drug delivery vehicles. Indeed, the
programmability of NA nanomaterials is expected to significantly impact diagnostics and
therapeutics for improved treatment outcomes in a wide range of diseases. These
materials can be tailored for highly specific molecular targeting, tissue penetration,
payload delivery, stimuli-responsiveness, biosensing, in vivo detection, and beyond.173 In
particular, SNAs represent an outstanding platform for constructing NA nanomedicines.
SNAs provide unmatched size control, stability, tissue penetration, cell internalization,
and controllable assembly allowing for extreme precision in personalizing and tailoring
nanocarriers for specific patients or diseases. Currently, no SNA platforms have been
approved by the FDA, although a first-in-human phase 0 clinical study of RNA
interference–based spherical nucleic acids in patients with recurrent glioblastoma has
recently commenced.174
The future of nanomedicine will require rational design strategies that exploit the
tunability of nanomaterials for specific purposes. In this review, a broader look at the
physical properties of nanocarriers and how they affect behaviors in vivo was discussed.
Although certain nanomaterials imbue functionalities, a holistic focus on nanocarrier size,
shape, mechanical properties, and surface properties will significantly improve the
pharmacokinetics and pharmacodynamics of administered nanomedicines. By utilizing
NAs as the main functional unit, all of these properties can be determined with a high
degree of precision via facile engineering of specific oligonucleotide sequences and

28

careful considerations of how they are assembled. Additionally, as a payload carrier,
multiple classes of therapeutic drugs can be incorporated and the release controlled from
the NA layer. It is envisioned that the controlled release strategies discussed in Section
2.5 can be incorporated into NA-based nanomedicine platforms of multiple shapes and
sizes, thus formulating platforms whereby the core material determines the general size
and shape, the outer layer determines molecular targeting and biological interface, and
the layers in between serve as drug reservoirs. Such a strategy is expected to
revolutionize the field of nanomedicine in the future.
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Figure 2.1. The tunability and versatility of nanomedicines. The profound tunability at
the nanoscale provides outstanding precision in the construction of nanomedicines. A
diverse toolbox of materials is available including polymersomes, liposomes, dendrimers,
and inorganic nanoparticles. The physical properties including size, shape, and
mechanical properties can be tailored for specific purposes. The surface properties can be
chemically altered to produce a specific ionic charge, modulate hydrophobicity, and
affect surface roughness. Finally, conjugation chemistry can decorate the surface of a
nanomedicine with a functional unit, such as a targeting components, e.g. mAbs,
aptamers, or peptides.
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Figure 2.2. The effect of size on nanocarrier fate. Some well-defined size ranges of
nanomedicines dictate their in vivo fate. Below 15 nm in diameter, nanomaterials are
rapidly excreted in urine due to renal filtration. Phagocytosis in the liver is increased
form sizes of 15 - 200 nm, mainly due to Kupffer cells but also due to alternate hepatic
cells for particles on the lower end of this range. From 100 - 200 nm, nanomaterials are
likely to be phagocytosed by marginal zone macrophages in the spleen, while particles
greater than 200 nm are sequestered in the red pulp of the spleen. Margination is
improved for particles less than 100 nm in diameter due to improved flow dynamics in
the blood. Tumor vasculature in particular is quite porous, with pores in the range of 100
- 780 nm, leading to increased passive accumulation of nanomaterials. However, larger
particles will still result in higher background accumulation in healthy tissue.
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Figure 2.3. The effect of shape on nanocarrier fate. Both surface curvature (top) and
aspect ratio (left) influence the in vivo fate of nanomedicines. Highly curved surfaces
show improved ligand display especially with regard to molecular targeting and
recognition. Curved surfaces are also more prone to opsonization and phagocytosis.
Lower surface curvature, e.g. disc-shaped or cube-shaped particles, show improved tissue
margination due to flow dynamics. Increasing he aspect ratio of a nanoparticle reduces
the rate of phagocytosis and improves tissue margination. Higher aspect ratios, including
filamentous particles, can show inherent cytotoxic effects, increased circulation times,
and improved penetration through tissue layers.
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Figure 2.4. The effect of mechanical properties on nanocarrier fate. Softer/flexible
particles show increased circulation times, improved transport through biological filters
(e.g., renal or splenic filtration), reduces phagocytosis, and increased adhesion of opsin
proteins - this is driven mainly by the deformability of the nanomaterial. Hard/rigid
particles show improved marination to endothelium and improved ligand display
regarding biomolecular interactions. However, this also leads to increased rate of Fcreceptor-mediated phagocytosis.
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Figure 2.5. Nucleic acid therapeutic multifunctionality. Nucleic acids are highly versatile
materials in the field of nanomedicine. Therapeutics include siRNAs, antisense
oligonucleotides, and aptamers. Structurally, they can form dendrimers, complex
nanostructures, or spherical nucleic acid platforms. They can also be used to load drug
either within/on the particle itself or intercalated within the nucleic acid layer.
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Chapter 3
Sustained Release of Antibody-Conjugated DNA Nanocarriers from a Novel
Injectable Hydrogel for Targeted Cell Depletion
3.1 Introduction
Dendrimer nanoparticles are given much attention for use as advanced therapeutic
nanocarriers.175 They are a highly versatile structural platform comprised of an initiator
core, branched substructures, and terminal functional groups. Based on simple basepairing principles and driven by specifically designed single-stranded regions, multigenerational dendritic nanostructures can be easily constructed using carefully designed
nucleic acids. The double-stranded regions can be used as a payload carrier for
intercalating drugs and from the terminal branches a variety of functional units can be
conjugated via complementary base pairing. A dendritic DNA nanocarrier loaded with
cytotoxic doxorubicin and conjugated to the G8 monoclonal antibody (mAb) was
developed by Code Biotherapeutics (Hatfield, PA), called 3DNA® (Figure 3.1). The
3DNA specifically targets cells expressing brain-angiogenesis-inhibitor 1 (BAI1) and
depletes them via release of the intercalated drug. This chapter focuses on the design of a
dynamic cell culture model used to test a controlled release formulation of 3DNA. The
overarching goal of this study was to improve upon current treatment modalities for
posterior capsule opacification (PCO), or secondary cataracts. It also serves as an
excellent example of the multifunctionality of dendritic NA nanocarriers.
3.1.1 Motivation
Cataracts are a slowly progessing vision impairment disorder caused by the break
down of fibers and proteins in the lens due to injury or aging. They are the leading cause
of vision impairment and blindness worldwide.176 Over 10 million cataract surgeries are
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performed annually and this rate is expected to double over the next 10 years.177 As a
result of this predicament, the World Health Organization released a global action plan to
increase access to cost-effective cataract surgeries.178–180
Surgery is currently the most effective method of treating cataracts. The
procedure involves removal of opacified tissue in the lens, replacing the lens with an
artificial intraocular lens (IOL). This surgery is safe and effective, and in most cases any
complications that arise are manageable by an opthalmologist.181 However, one major
risk involved in cataract surgery is the emergence of PCO, also known as secondary
cataracts. During the wound healing process post cataract surgery, a population of fibrotic
cells migrates to the lens capsule. These fibrotic cells wrinkle the lens, and over time lead
to significant vision loss.182 PCO occurs in up to 40% of adult patients and nearly all
children after cataract surgery.183 Thus, improving the strategy for PCO prevention
represents a pressing issue.
Currently the most effective treatment for PCO is neodymium-doped yttrium
aluminum garnet (Nd:YAG) laser capsulotomy, which improves visual acuity by
rupturing the opacified tissue with short, high-powered pulses of light.184 However,
Nd:YAG therapy is not available world-wide and there are often side effects from
treatment including intraocular pressure spikes, cystoid macular edema, retinal
detachment, and IOL damage.185–188 Improvements in surgical techniques, IOL design,
and understanding the influence of biomaterials on IOL performance have improved
patient outcomes regarding PCO, but it still presents a significant burden on patients and
the healthcare system.189–192 Cytotoxic drugs and chemicals, including antiinflammatories, immune-modulating agents, anti-cell migration compounds, and
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cytotoxins have been administered after cataract surgery to prevent the initial migratory
cell response of PCO, but these drugs eliminate cells non-specifically and drug diffusion
to surrounding tissue can initiate an inflammatory response.193
With the increase in cataract surgeries expected worldwide, there is an urgent,
unmet need for more effective, prophylactic treatment strategies to prevent PCO. The
fibrotic cell response that leads to PCO is due to the migration of a specific subpopulation
within the lens known as Myo/Nog cells.194–196 Myo/Nog cells were first identified in the
chick embryo blastocyst by their expression of the skeletal muscle specific transcription
factor MyoD and the bone morphogenic protein inhibitor noggin.197,198 Previous
experiments revealed the commitment of these cells to the skeletal muscle lineage
regardless of their environment.194 In cultures of human lens tissue, Myo/Nog cells
differentiate into myofibroblasts in response to wound healing.194,195 Depletion of
Myo/Nog cells in short-term and long-term cultures of human lens tissue prevented the
accumulation of myofibroblasts.194,195 A third marker of Myo/Nog cells is expression of
BAI1 recognized by the G8 mAb.197,199,200 The anti-BAI1 G8 mAb specifically targets
Myo/Nog cells for depletion by complement mediated cell lysis or when conjugated to
dendritic DNA nanocarriers loaded with cytotoxic doxorubicin (G8:3DNA:Dox).194–
197,199,201,202

Injections of G8:3DNA:Dox into the rabbit lens capsule during cataract

surgery significantly reduced clinical signs of PCO after 28 days.196
A controlled release formulation for 3DNA would significantly improve clinical
outcomes for patients after cataract surgery. One major advantage of a controlled release
compared to a bolus injection is that humans PCO develops more slowly in humans than
it does in rabbits.203 Additionally, over time Myo/Nog cells from the ciliary body may
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traverse the zonules and repopulate the lens.204 In this study, we tested a sustained
delivery formulation for delivery of G8:3DNA:Dox in cultures of human
rhabdomyosarcoma cells containing a subpopulation that expresses BAI1.205 The
formulation consists of a biodegradable, in-situ forming PLGA-PEG-PLGA hydrogel that
releases G8:3DNA:Dox for up to 4 weeks.206 Herein, we compare a bolus dose versus
hydrogel-mediated sustained delivery of G8:3DNA:Dox for cell targeting and depletion
within a dynamic, microfluidic flow environment representing the fluid flow in the lens
(Figure 3.2). The hypothesis underlying this work is that administration of the drug in a
sustained delivery formulation will specifically eliminate the subpopulation of cells that
express BAI1 more effectively than a bolus dose in long term, dynamic systems.
3.2 Materials and Methods
3.2.1 Materials
Triblock copolymer, PLGA-PEG-PLGA, with d,l-LA/GA ratio of 15/1,
PLGA/PEG ratio of 2/1, and PEG with a molecular weight 1,500 Da was purchased from
PolySciTech, Inc. (West Lafayette, Indiana). Poly(ethylene glycol) Mn 400 (PEG400)
was purchased from Alfa Aesar (Harverhill, MA). G8:3DNA:Dox nanocarriers were
obtained from Genisphere, LLC. Rhabdomyosarcoma (RD) cells were purchased from
the American Type Culture Collection (ATCC CCL-136) (Manassas, VA). Phosphatebuffered saline (PBS) was purchased from VWR (Radnor, PA).
3.2.2 3DNA Nanocarrier Synthesis and Formulation
The term 3DNA refers to a novel, dendritic nanocarrier comprised of nucleic acid
strands designed specifically for step-wise hybridization and layer-by-layer assembly,
described previously.195,207,208 It consists of approximately 3000 DNA bases with 36
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single-stranded peripheral regions. The approximate molecular weight, diameter, and zeta
potential of 3DNA are 106 Da, 60 nm, and -28 meV, respectively. Doxorubicin (SigmaAldrich, St. Louis, MO) was intercalated into double-stranded regions of 3DNA by
incubating at room temperature at a ratio of 500:1 Dox:3DNA, resulting in >99% loading
efficiency. The G8 mAb was conjugated to a DNA oligonucleotide via amine-tosulfhydryl attachment using a heterobifunctional crosslinker (Pierce Crosslinking Kit;
ThermoFisher Scientific) and hybridized to 3DNA peripheries via complementary base
pairing. The final 3DNA construct contained 4 mAb per particle and had a diameter of
120 nm.
3.2.3 Injectable Hydrogel Formulation and Characterization
Solutions consisting of 10 (w/v)% PLGA-PEG-PLGA, 1.6 (v/v)% PEG400 were
mixed on a tube rotator at 4oC for 24 h. This formulation was previously shown to
transition into a hydrogel at 35oC with acceptable physical and optical properties.206
Solutions were lyophilized and reconstituted with G8:3DNA:Dox in PBS to a final
concentration of 0.7 ng 3DNA/µL. Solutions were kept at 4oC until ready for use.
To confirm the formation of a physical hydrogel, the viscoelastic properties of the
hydrogel were investigated using an ATS RheoSystem NOVA Rheometer (State College,
Pennsylvania). A stress-controlled temperature ramp was performed between two flat
plates of diameter 25 mm with the gap between the plates set to 0.3 mm. The heating rate
was 1°C/min and the stress was 4 dyn/cm2 at a frequency of 1.0 rad/s. Optical clarity was
determined by measuring light transmittance on a 96-well plate at 35°C using a UV/Vis
spectrophotometer (SpectraMax M3, Molecular Devices). The wavelength range was
between 400 to 700 nm. Release of G8:3DNA:Dox from hydrogels was performed in a
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400 µL chamber under physiological fluid flow (2.5 µL/min) and detected in the release
media via a fluorophore (Alexa647) conjugated to the nanocarriers.
3.2.4 Cell Culture and Cytotoxicity Tests
A Myo/Nog-like subpopulation was identified in cultures of RD cells by colocalization of antibodies to noggin and BAI1.205 Therefore, this cell line was utilized to
observe the targeting and depletion of BAI1+ cells with exposure to G8:3DNA:Dox.
Cells were cultured in complete Dulbecco's Modified Eagle Medium (DMEM, 10% FBS,
1% antibiotic/antimycotic) in a 37oC cell incubator (VWR) with 5% CO2. Cell viability
tests were performed on cells cultured on 96-well tissue culture plates (VWR). To assess
cytotoxicity, these cells were incubated with an aliquot of either hydrogel, 42 ng of
G8:3DNA or 42 ng of G8:3DNA mixed with hydrogel. Viability was determined via
calorimetric MTT cell viability assay (PromoCell).
3.2.5 Dynamic Cell Culture Experiments
RD cells were cultured in a standard 24-well tissue culture plate, which has a
similar diameter (15.62 mm) to the lens capsule (12.53 mm).206 Each well was capped
using polydimethylsiloxane (PDMS) lens molds of the anterior capsule to form chambers
of 400 µL volume with inlet and outlet ports for fluid flow (Figure 3.3). Cells were
seeded into devices at a density of 2x105 cells/mL and allowed to attach overnight. Then,
42 ng of G8:3DNA:Dox nanocarriers as a bolus or with hydrogel was injected into each
device. A syringe pump was used to maintain a flow rate of fresh media at 2.5 µL/minute
for up to 7 days. Cells were stained via the covalent, dead cell specific Live-or-Dye
NucFix™ Red Staining Kit (Biotium, Fremont, CA) and then immediately fixed with 2%
paraformaldehyde followed by permeabilization with 0.5% Triton X-100. BAI1 was
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localized with the G8 IgM mAb.200 The primary antibody was visualized using affinitypurified, F(ab’)2 goat anti-mouse IgM µ-chain conjugated with a fluorophore (Biotechne, Minneapolis, MN). Finally, nuclei were stained with Hoechst dye (Bio-techne,
Minneapolis, MN). Immunofluorescence was analyzed with an inverted fluorescent
microscope (Zeiss) equipped with AxionCam ICm1 camera and Multi-Image-04 ZEN 2
lite image analysis software program. Cell counts and identification were performed
using ImageJ.
3.3 Results
The RD human rhabdomyosarcoma cell line was used to test the efficacy of the
drug delivery system. About 12(±9)% of the RD136 cell population is BAI1+.205 A novel
microfluidic system was designed to culture the cells in a small volume and under
dynamic fluid flow in order to mimic the lens capsule environment more closely (Figure
3.3). Thus, G8:3DNA:Dox nanocarriers, either as a bolus or with a sustained release
hydrogel, could be injected into each well and cell targeting could be compared over
time.
3.3.1 Hydrogel Characterization
This study utilized a PLGA-PEG-PLGA triblock copolymer hydrogel for its
injectability, controlled gelation temperature, and ability to sustain the release of
G8:3DNA:Dox. Rheological characterization is shown in Figure 3.4A. The storage
modulus of the hydrogel is near zero below 30oC, suggesting a Newtonian fluid with
good injectability. It then spikes between temperatures of 30-45oC. Qualitatively, gelation
can be confirmed via the vial-inversion method209 and it was confirmed that the hydrogel
transitions at a temperature of 35oC. Rheology revealed a storage modulus of 170.5 Pa at
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this temperature. The storage modulus reaches its peak at 37oC (474.6 Pa) before
beginning to decline until reaching a final value of 35 Pa at 49oC. Furthermore, the
hydrogel appears optically clear. The measured light transmittance over the wavelengths
470-750nm is greater than 80% for the hydrogel alone (Figure 3.4B). After loading with
G8:3DNA:Dox, the light transmittance is slightly improved and retains greater than 80%
transmittance over wavelengths 420-750nm.
In Figure 3.4C we show the release of G8:3DNA:Dox from hydrogels in a 400 µL
chamber under constant fluid flow of 2.5 µL/min. These release conditions represent the
fluid flow within the lens and the small volume allows for a smaller diffusion gradient
compared to conditions such as infinite sink. In the microfluidic model conditions, the
release of the nanocarrier is sustained for 672 hours, or four weeks. After 24 hours, only
1.2% of nanocarriers are released, indicating that no burst release is occurring and that
the transport of the nanocarriers out of the gel is controlled. A cell viability assay was
used to determine the cytotoxicity of PLGA-PEG-PLGA hydrogel and G8:3DNA
nanocarriers without intercalated doxorubicin. The results are shown in Figure 3.5.
Aliquots of hydrogel, G8:3DNA nanocarriers, and a combination of the two showed cell
viability greater than 90% indicating that the hydrogel and targeted nanocarrier are
nontoxic without the drug payload.
3.3.2 Dynamic Cell Studies
We compared a bolus dose and sustained delivery of G8:3DNA:Dox for their
ability to kill BAI1+ cells in long term, dynamic cell cultures. The results are shown in
Figure 3.6. Cells in our experiments showed an average expression of 15.9% BAI1+
cells. Relative expression was reduced over time as cells proliferated. The greatest rate of
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off-target (BAI1−) depletion was 3.2% after 24 hours in cells treated with the bolus dose.
Otherwise, less than 1% of BAI1− cell depletion was observed over the course of the
experiment.
The bolus dose of G8:3DNA:Dox showed improved BAI1+ cell targeting after
the first 24 hours but the relative targeting declined steadily over the course of the week.
At 24 h, relative depletion of 26±15% and 10.4±14.2% BAI1+ cells was observed for
bolus and hydrogel treated cells, respectively. Note that these averages are statistically
similar. By day 3, only 5.5±2.3% of BAI1+ cells were depleted in cultures treated with
the bolus. On day 7 < 2% of BAI1+ cells were depleted. The sustained release of
G8:3DNA:Dox showed increased targeting of BAI1+ cells over the course of the. By day
3, 47.9±13.4% of BAI1+ cells were depleted. The result is similar at day 5, with
45.2±21.5% BAI1+ cells targeted. At day 7, 74.2±21.4% of BAI1+ cells were non-viable
with release of G8:3DNA:Dox from the hydrogel. Images of specific targeting of BAI1+
cells by G8:3DNA:DOX nanocarriers is shown in Figure 3.7.
3.4 Discussion
PCO is expected to rise with the rate of cataract surgery over the next 10 years.
There are no reliable indicators of vulnerability to developing PCO, and therefore,
effective methods of preventing its development are imperative to preventing vision loss
in patients, especially for those lacking access to Nd:YAG laser therapy. A large barrier
in this case is the challenge of effective drug delivery to treat ocular disorders due to the
unique physiological barriers present within the eye, ocular fluid dynamics, difficulty in
accessing posterior portions of the eye, and low drug bioavailability.210–212 The structure
of the lens capsule and the fluid dynamics therein make intraocular drug delivery
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difficult.213,214 Due to these challenges, many effective ocular treatments are hindered by
the need for multiple doses or invasive surgical interventions. As the healing process after
cataract surgery can last for weeks, it is imperative that the release of a therapeutic is
sustained.
At the forefront of ocular drug delivery are thermoresponsive hydrogels and
nanoarchitectures that can achieve a sustained release of therapeutics within the eye,
including hydrophilic, hydrophobic, and bioactive drugs.215–218 Injectable, in situ gelling
systems in particular present an excellent area of focus due to the ability to provide
minimally invasive, site specific dosages of drugs for long term administration.219,220 In
particular, PLGA-PEG-PLGA triblock copolymer hydrogels have emerged as excellent
vehicles for ocular therapeutics due to biocompatibility and sustained therapeutic
release.221–223 When in contact with the aqueous humor within the eye, PLGA degrades
into its monomers lactic acid and glycolic acid which are metabolized by natural
biological processes. Additionally, PLGA-PEG-PLGA hydrogels have tailorable
mechanical and optical properties and the capability to sustain therapeutic release.
Similar polymers have been studied previously and show no sign of toxicity.224,225 We
show similar observations for our hydrogel in Figure 3.5.
In a previous study, a bolus injection of G8:3DNA:Dox administered in a static
environment required two doses to deplete all BAI1+ cells in cultures of human lens
tissue.195 Therefore, we developed a microfluidic system within a 24-well tissue culture
plate as a high-throughput method to investigate the long-term prophylactic capabilities
of G8:3DNA:Dox in a dynamic environment. Microfluidic designs are able to simulate
complex physiological processes and environments to better assess fluid dynamics and

44

biochemical concentration gradients.226–228 This allowed us to compare a bolus dose of
G8:3DNA:Dox and an injectable, sustained release formulation of G8:3DNA:Dox in a
more physiologically relevant environment. In dynamic cultures of RD136 cells in which
a subpopulation expresses BAI1, we see that after three days the bolus injection of
nanocarriers targets less than 10% of BAI1+ cells. This value continues to decrease for
the 3DNA bolus injections until nearly no BAI1+ cells were targeted at 7 days. This is
due to the high turnover of fluid which occurs in 3-4 hours within the chamber, which
would rapidly reduce the nanocarrier concentration. Conversely, G8:3DNA:Dox
nanocarriers in hydrogel continue to deplete BAI1+ cells at an increasing rate over the
course of 7 days. On day 7, over 70% of all BAI1+ cells were targeted and killed by
nanocarriers released from the hydrogel. This significant difference in cell depletion is
due to the transition at physiological temperatures to a non-flowing hydrogel that resides
within the culture chamber. The hydrogel subsequently continues to release nanocarriers
leading to extended exposure to cells over a longer time period. In all cases,
G8:3DNA:Dox specifically targeted the BAI1+ subpopulation via the conjugated G8
mAb, which is necessary to avoid non-specific cell depletion. While it is unknown
whether BAI1+ cells remaining in these cultures arose from the proliferation of
untargeted BAI1+ cells or from de novo expression of this molecule, these results
demonstrate that sustained delivery of the drug in the hydrogel formulation is more
effective than bolus delivery for targeting this population.
This work can be compared to previous in vivo studies involving bolus injections
of G8:3DNA:Dox in adult rabbits during cataract surgery.196 Animals treated with
G8:3DNA:Dox showed little to no clinical evidence of PCO (determined via slit lamp
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analysis and histology) 28 days after cataract surgery. However, BAI1+ Myo/Nog cells
remained in the lens and more Myo/Nog cells may enter the lens by traversing the
zonules from the ciliary body,204 suggesting that vision impairment can still emerge over
time. In the system used here, the ability of a bolus injection of G8:3DNA:Dox to deplete
BAI1+ cells began to wane after only 3 days. The sustained hydrogel release, on the other
hand, continues to specifically kill BAI1+ cells for at least 7 days.
3.5 Conclusions
Administration of a drug that prevents PCO would reduce vision loss in patients
and significantly lessen the burden on the healthcare system. PCO can be reduced by
injecting a drug that targets Myo/Nog cells during cataract surgery. However, the
physiological conditions within the lens indicate that the concentration of a drug will
decline over time. Herein we showed that a biodegradable, in situ forming hydrogel
loaded with G8:3DNA:Dox targeted nanocarriers significantly outperformed a bolus
injection in killing BAI1+ cells in dynamic cell cultures. The hydrogel is in situ forming,
non-toxic and optically clear at 37oC, and therefore, could be injected into the lens
capsule during cataract surgery. Over time, the hydrogel would degrade into nontoxic
components. A microfluidic device utilizing cells cultured on 24-well plates under
physiological fluid flow allowed for high-throughput comparisons of BAI1+ cell toxicity
over one week via treatment with either a bolus injection of G8:3DNA:Dox or within our
PLGA-PEG-PLGA hydrogel formulation. Over time, BAI1+ cells were targeted at a
much higher rate using the sustained release hydrogel. A bolus injection did kill BAI1+
cells within the first 24 hours of treatment; however, nearly all remaining BAI1+ cells
were viable after 7 days, while sustained release of the drug continued to kill cells over
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the course of a week. We expect that targeting would extend for longer than 7 days, as
G8:3DNA:Dox was observed to release from the hydrogel for up to 4 weeks. This
hydrogel formulation has potential for sustaining drug delivery to prevent PCO.
This work also accentuates a main focus of this dissertation, i.e. the advantages
and versatility of NA nanocarriers. The 3DNA nanocarrier is a highly customizable
platform for conjugating antibodies for the specific delivery of therapeutics. It is
formulated using facile manipulation of NA sequence to control the directed assembly of
a multigenerational nanocarrier construct. The platform nature of NA nanotechnology
allows for novel applications in a number of pressing diseases - indeed, just this year
Code Biotherapeutics has received significant funding to use 3DNA as a treatment for
genetic therapy in rare liver disease.229 It is expected that dendritic NA nanocarriers will
prove advantageous for site-specific administration of drugs or delivery to protected
regions such as ocular spaces, the skin, or the blood-brain-barrier, where systemic
circulation is avoided or not necessary. However, in systemic circulation, NA dendrimers
suffer from many of the issues discussed in the previous chapter with regard to stability
and degradation, tissue localization, and immunogenicity. Additionally, dendrimers
cannot exploit the EPR effect in tumors without further conjugation with PEG or to a
nanoparticle core.118,230 Thus, for systemic circulation and delivery to solid tumors, a
more sophisticated architecture is required.
Spherical nucleic acids (SNAs) emerged in the late 20th century as a method of
rationally assembling macrostructured networks of gold nanoparticles (AuNPs).231 Since
then, SNAs have become a class of their own due to their unprecedented capabilities of
long circulation, stability, and tissue penetration. They have also been utilized in novel
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ways to carry drug payloads.172,232 The following chapter will describe the
characterization of NA monolayers on gold surfaces and investigate methods by which
the NA shell-layer can be manipulated for the purpose of controlling drug release.
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Figure 3.1. Schematic of 3DNA nanocarriers. 3DNA is a novel, dendritic nanocarrier
comprised of nucleic acid monomers designed specifically for step-wise hybridization
and layer-by-layer assembly. It contains approximately 3000 DNA bases, 36 singlestranded peripheral regions, and four conjugated mAbs per particle. Doxorubicin is
intercalated into double-stranded regions of 3DNA. The final diameter of 3DNA is 120
nm.
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Figure 3.2. Schematic of experimental design. Cells were cultured in a 24 well plate
capped with PDMS and fresh media was flowed over the culture at a rate of 2.5 µL/min.
G8:3DNA:Dox nanocarriers as a bolus or within a hydrogel were injected into the well at
the beginning of the experiment. Upon injection and incubation at 37oC, the hydrogel
transforms into a non-flowing gel and remains in the chamber for the entirety of the
experiment. The 3DNA is released slowly over the course of 4 weeks.
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Figure 3.3. The dynamic cell culture design. Close up image of the cell culture chambers in each
well. Cells are cultured on the bottom of the plate. Constant fluid flow was maintained within the
chamber and throughout the tubing. The total volume within each well was 400 µL.
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Figure 3.4. Characteristics of G8:3DNA:Dox/PLGA-PEG-PLGA hydrogel. (A)
Rheological measurements of the hydrogel storage modulus as a function of temperature.
A peak at physiological temperature confirms that the solution is transitioning to a
hydrogel. (B) Optical clarity presented as percentage of light transmittance from 400750nm wavelength. PLGA-PEG-PLGA(), G8:3DNA:Dox/PLGA-PEG-PLGA().
Optical clarity above 80% shows that the gel will not impair vision. (C) Release of
G8:3DNA:Dox from PLGA-PEG-PLGA hydrogel in microfluidic device over time.
Nanocarriers released from the hydrogel for up to four weeks.
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Figure 3.5. Results of MTT cell viability assay. after treating cultures with PLGA-PEGPLGA hydrogel, nanocarriers in PBS, and nanocarriers with hydrogel. Cell viability was
measured without the presence of Dox. All components retain above 90% cell viability
indicating that they are non-cytotoxic.
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Figure 3.6. BAI1+ cell targeting in dynamic cell cultures. Cells were treated with
G8:3DNA:Dox nanocarriers as a bolus () or with hydrogel () at t0. The percentage of
BAI1+ cells that were targeted were monitored every other day for 7 days. Significant
differences are seen in targeting percentage between bolus and sustained release systems,
denoted with an asterisk. (p < 0.05).
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Figure 3.7. Specific targeting of BAI1+ cells over 7 days. Cells were treated with
G8:3DNA:Dox nanocarriers in a sustained release hydrogel (G8:3DNA:Dox/PLGAPEG-PLGA) or as a bolus injection (G8:3DNA:Dox/PBS). Cell nuclei (blue), dead cells
(red), and BAI1+ cells (green) were stained. Targeted cells appear yellow due to
colocalization of BAI1+ cells and dead cells (green + red). Nanocarriers given as a bolus
show very little targeting after 7 days. Nanocarriers released from hydrogel continue to
target BAI1+ cells at an increased rate over 7 days.
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Chapter 4
Investigating the Nanoarchitectures of DNA Monolayers on Gold Surfaces
4.1 Introduction
Dendrimers represent a simple application of DNA nanocarrier technology driven
by complementary base pairing and the careful design of single-stranded overhangs to
facilitate branched nanostructures. Sequence selection and layer-by-layer assembly gives
precise control over size and shape, multifunctionality, stability, and ability to conjugate
functional units or load therapeutics.233 Such structures provide an exquisite platform for
the synthesis of versatile nanocarriers incorporating bioactive functionality such as
sensitive biomolecule detection, high drug loading, and/or antibody display.234 For site
specific administration, dendritic DNA likely represents the most elegant solution for
targeted delivery of therapeutics, as seen in the previous chapter. However, dendritic
DNA nanostructures perform poorly in systemic circulation due to the physiological
barriers of nucleic acids delivery including immune stimulation, poor stability, low
transfection efficiency, and short biological half-life.235–237
The rational design of nucleic acid nanostructures can provide a similarly
multifunctional template for drug delivery while also improving bioavailability and the
capacity to overcome these physiological barriers. Specifically, spherical nucleic acid
nanostructures (SNAs) have proven to be highly capable of withstanding the harsh
conditions of systemic circulation. The most common form of spherical nucleic acid is
formulated using a gold nanoparticle (AuNP) core. Gold is highly advantageous due to
the precise control over the size and shape of AuNPs, optical properties that substantially
assist imaging and detection for diagnostics, stability and bioinert nature, and its plethora
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of therapeutic effects on several diseases.238 Oligonucleotides can be self-assembled
orthogonally about the AuNPs to form a biopolymer brush arrangement via modification
of either the 3' or 5' terminal ends with an alkylthiol moiety. The addition of cations, or
salt-aging, is used to screen the negative charges between neighboring DNA strands in
order to increase the surface density significantly.239 The steric density and local
concentration of salt ions causes DNA-AuNPs to be extremely stable in physiological
media, resistant to protein adhesion, show reduced immune response, and allows them to
be efficiently internalized by cells without the need for additional transfection reagents.
As a result, the DNA-AuNP nanocarrier presents itself as a highly effective vehicle for
systemic delivery of drugs. However, the flexibility of NAs, the possibilities of intra- and
inter-molecular interactions, and the poorly understood interactions of parallel DNA
present a great mystery as to the nanoarchitecture of NA layers conjugated to gold.
In general, the NA layer conjugated to AuNPs can exist in either a flat, folded,
coiled, or stretched state. It was hypothesized that by manipulating a DNA monolayer to
adopt these different structures, the architecture can be exploited for controlled release of
therapeutic drugs via restrictions to drug transport through the DNA layer. This chapter
focuses on characterizing these different NA layers on gold and determines methods by
which the nanoarchitectures can be controlled. To investigate the degree to which these
layers can be manipulated, self-assembled DNA monolayers were formed on planar gold
films and 15 nm AuNPs. The planar films were analyzed via quartz crystal microbalance
with dissipation (QCM-D) and the AuNP layers were analyzed via dynamic light
scattering (DLS).
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4.2 Quartz Crystal Microbalance with Dissipation
4.2.1 Introduction and Theory
A quartz crystal microbalance (QCM) measures mass per unit area by detecting
the change in frequency of a quartz crystal resonator, which is proportional to the
thickness of the crystal and thus any adlayers conjugated thereto. It works based on the
inverse piezoelectric effect, i.e., the application of voltage results in mechanical
deformation of crystalline materials with certain symmetrical properties. An alternating
current therefore leads to a cyclical or oscillatory deformation. By applying a voltage that
matches the crystal’s resonance frequency or multiples thereof (overtones), a standing
wave is generated inside the crystal. Different oscillations will result depending on the
cut of the crystal. QCM uses AT-cut crystals which vibrate in the thickness-shear mode
with the two surfaces moving in an antiparallel fashion. Dissipation monitoring (QCM-D)
allows one to measures the dampening of the shear wave as it propagates through the
adsorbed layer and the bulk solvent. QCM-D operates via the “ring-down” technique
where the voltage is intermittently turned off and the oscillations are allowed to decay.
The decaying oscillations generate a voltage via the piezoelectric effect. Thus, QCM-D
produces two parameters per overtone, the oscillation frequency (f, Hz) and the energy
dissipation (D, unitless). For these purposes the quartz crystal must be coated by an
electrode, which is commonly gold.
The induced oscillations in quartz crystals are exceptionally stable and sensitive
to changes in adsorbed mass, hence their utilization as a microbalance (Figure 4.1). For
thin, homogenous, rigidly coupled, and non-dissipative films, changes in the oscillation
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frequency (f ) show a linear relationship to the mass of the adlayer via equations
derived by Sauerbrey240:
∆𝑚 = −𝐶 ∙

∆𝑓
𝑛

where m is the change in areal mass density of the film, f is the change in
oscillating frequency, n is the overtone number, and C is the mass sensitivity constant
(17.7 ng/(cm2∙Hz) for a 5MHz crystal). When the above assumptions are violated, which
is usually the case of viscoelastic films or sufficiently thick films, the dissipation is
necessary to characterize the adlayer. In these cases, a more intense mathematical model
is necessary.
4.2.2 Viscoelastic Modeling
Biomolecular films, being generally highly hydrated polymers that exhibit
viscoelastic properties, cause the Sauerbrey relationship to be invalid. Thus, a more
advanced analysis is called for. The most appropriate connection between the measured
parameters via QCM-D and the physical characteristics of a viscoelastic polymer film is
achieved using a continuum mechanics approach. Most often this is done by fitting a
Voigt model of viscoelastic films, represented by a purely viscous damper and purely
elastic spring connected in parallel. The Voigt model has been derived for used on QCMD results by Voinova et al,241 and the relationship between QCM-D parameters and the
viscoelastic characteristics of the film are given by the following equations:
∆𝑓 = −
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Where ρ0 and h0 are the density and thickness of the crystal, η3 is the viscosity of
the bulk liquid, 𝛿 3 is the viscous penetration depth of the shear wave in the bulk liquid, ρ3
is the density of liquid, and 𝜔 is the angular frequency of the oscillation. Thus, the
adlayer is described by four parameters: density (ρ1), viscosity (η1), shear elasticity (µ1),
and thickness (h1). Using known values to describe the properties of the crystal and the
bulk liquid, and subsequently measuring f and D at multiple overtones, only one
value, either layer thickness or density, must be independently verified or assumed in
order to fit the equation. For DNA films, we use an assumed density of 1.06 g/cm3.
Therefore, via an iterative fitting of QCM-D parameters to the Voigt model relevant
parameters about the thickness and viscoelastic character of bound nucleic acid layers can
be extracted.
4.3 Dynamic Light Scattering
When a monochromatic beam of light encounters a solution of macromolecules,
light scatters in all directions (Rayleigh scattering) depending on the size and shape of the
molecules. The intensity fluctuations caused by Brownian motion in solution can be
analyzed to calculate a diffusion coefficient (Dτ). Dynamic light scattering (DLS), also
known as photon correlation spectroscopy, is a technique that relates this motion to the
size of particles via the Stokes-Einstein equation:
𝐷𝜏 =

𝑘𝐵 𝑇
6𝜋𝜂𝑅ℎ

where kB is the Boltzmann coefficient, T is an absolute temperature, η is the viscosity of
medium, and Rh is the hydrodynamic diameter of the molecule. Since large particles
diffuse more slowly than small particles, this method allows for an accurate estimate of a
range of particle sizes in solution. The most popular data analysis method known as
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cumulant analysis provides mean values for the diffusion coefficient and thus determines
a Gaussian-like distribution around the mean size values. For spherical particles, such as
DNA-AuNPs, the mean values approximate very closely the actual size values of the
particles.
4.4 Materials and Methods
4.4.1 QCM-D Preparation
All QCM-D experiments were performed on a Q-Sense analyzer from Q-Sense
(Gothenberg, Sweden) using gold coated quartz crystal sensors. The sensors were precleaned upon receipt and immediately after experiments and not used more than 4 times.
Sensors and all tubing were thoroughly rinsed with 0.01% SDS. Then, sensors were
cleaned in a UV/ozone chamber for 10 min, immersed in a base piranha solution (5:1:1
v/v water, H2O2 (30%), NH4OH (30%)) at 75oC for 5 min, dried using N2, and cleaned
again in a UZ/ozone chamber for 10 min. Baseline frequency and dissipation
measurements were observed in air and water/phosphate buffer before starting
experiments. Sample introduction was performed via manual syringe injection done
slowly over the course of one minute using sufficient volume to ensure total buffer
replacement in the sensor chamber.
4.4.2 DNA Oligonucleotide Preparation
Thiolated oligonucleotides were shipped lyophilized in their oxidized form and
must be reduced before use. Oligonucleotide stocks were prepared in TE buffer (10 mM
Tris-HCl, pH8.0 and 1 mM EDTA) at a 1 mM concentration. Stock solutions were mixed
with 50 mM DTT in phosphate buffer (0.2 M, pH 7.4) for 3 hours. The reduced DNA
mixtures were desalted using NAP-10 gravity-flow sephadex columns. Concentration of
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DNA preparations was validated by their UV absorbance at 260 nm wavelength. All
reduced DNA solutions were brought to working concentrations using deionized water or
PBS. The hybridized dsDNA molecules were prepared by mixing equimolar amounts of
each oligonucleotide and its complement at 80oC for 10 min followed by slow cooling to
room temperature. Sequences used were a single- and double-stranded sequence of 19 bp
(ss19 and ds19, respectively) and a single-stranded sequence of 52 bp (ss52). They are
shown in Table 4.1.
4.4.3 ssDNA and dsDNA Binding to QCM-D Sensors
A single-stranded, 19 nt DNA oligonucleotide and an identical double-stranded
oligonucleotide with a 13 nt complement and 6 nt spacer tail (ss19 and ds19,
respectively) were dissolved in water at concentrations from 0.3 to 4 µM. Samples were
injected into QCM-D chambers after establishing a baseline in water and allowed to bind
to the gold surface for one hour. The chamber was then washed with water to remove
unbound material and left for a final baseline. Next, 0.3 µM solutions of each DNA
oligonucleotide were mixed with NaCl from 0.2 to 1 M and immediately injected into
chambers containing cleaned sensors in water. Oligonucleotides were again left to bind
for one hour before washing with water.
4.4.4 Klenow Experiments on QCM-D
The ss19 strands was hybridized to the ss52 strand by mixing at 80oC for 10 min
followed by slow cooling to room temperature. The hybridized strand was bound to a
clean QCM-D sensor in water and allowed to bind for one hour before washing with
water. Next, the bound ss52 sequence was washed with 1X DNA polymerase buffer
including free nucleotides (dNTPs) at a concentration of 33µM. To this solution 1µL of
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Klenow enzyme was added (2 U/µL). The enzyme mixed with the oligonucleotide layer
for 6 hours before being washed with water for a final baseline.
4.4.5 Dynamic Light Scattering Experiments
DLS was performed using a Malvern Zetasizer nano series Z-S90. Experiments
were performed by loading AuNPs at a concentration of 4.7 x 1012 nanoparticles/mL into
1 cm2 clear DLS cuvettes. Measurements were performed at 25oC and done as cumulants
analysis to provide a mean average intensity and estimate hydrodynamic diameter of
particles in solution. Diameter ranges are given as % mean intensity.
4.4.6 Klenow Experiments on DNA-AuNP
AuNPs conjugated to ss19 DNA were hybridized with ss52 strands by mixing at
80oC for 10 min followed by slow cooling to room temperature. The particles were
resuspended in 1X DNA polymerase buffer including free nucleotides (dNTPs) at a
concentration of 33µM. To this mixture 1µL of Klenow enzyme was added (2 U/µL).
Samples from the reaction tube were extracted at certain time points, mixed with EDTA,
and heated to 75oC for 10 min to remove enzymatic activity. They were then centrifuged
and resuspended in water. The resultant samples were loaded into a 2% agarose gel to
investigate enzymatic activity over time.
4.5 Results
4.5.1 ssDNA and dsDNA Binding to Gold QCM-D Sensors
The modeled viscoelastic parameters from ss19 layers bound at increasing
concentration is shown in Figure 4.2. The ss19 layer reaches its largest thickness at the
lowest concentration of 0.3 µM. In this case, the thickness is 4.5 nm on average, equal to
about 70% of the theoretical strand length. This indicates a relaxed, coiled layer of
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upright ssDNA. The thickness then decreases in a non-linear fashion as the concentration
increases. The lowest observed thickness of 1.3 nm occurs at a concentration of 3 µM,
which would equate to an almost completely flat layer of ssDNA. The 4.5 nm ssDNA
layer is also the stiffest, having a shear modulus value of 0.7 MPa. For the 1.3 nm (flat)
layer, the shear modulus value is 0.05 MPa on average, and the softest layer observed.
Viscosity estimates interestingly show a peak at 2 µM and a local minimum value of 1.4
mPas at 3 µM, with the average viscosity for all layers being 1.6 mPas.
The modeled viscoelastic parameters from ds19 layers bound at increasing
concentration is shown in Figure 4.3. Again we see the largest thickness achieved at the
lowest concentration. Here, the ds19 forms a layer about 5.5 nm thick, a full nanometer
thicker than the ss19 layer at the same concentration. The ds19 layer also decreases in
thickness as the concentration increases, although in this case the decrease is more linear
(R2 = 0.978). The lowest thickness observed is 1.1 nm at 4 µM, which is lower than the
theoretical thickness of a flat dsDNA layer (2 nm), and thus suggests either denatured
dsDNA or sparse surface coverage. Likewise, the estimates of shear modulus are
decreased as concentration increases. The thickest, and also stiffest, layer has an
estimated shear modulus of 0.29 MPa. Compared to the shear modulus of the same
concentration of ssDNA (0.7 MPa), the ds19 layer is more than twice as soft. However, at
the higher concentrations, where the dsDNA layer is lying flat, the resultant layers are
more than twice as stiff as the flat ssDNA layers. Viscosity estimates remain similar for
all concentrations of ds19 tested, averaging about 1.5 mPas, marginally lower than that
for ss19 (1.6 mPas).
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4.5.2 Effect of Salt Concentration on the Structure of ssDNA and dsDNA Monolayers
Addition of cations is known to increase the surface density of NA monolayers.
This increase in surface density, when strands are oriented normal to the surface, results
in a stretching or uncoiling of the NA layer. We see the same results in Figure 4.4. The
ss19 layer increases in thickness with increasing NaCl concentration reaching the highest
value of 7.5 nm at 0.4 M NaCl, which is more than one nanometer thicker than the
theoretical strand length. At this concentration the shear modulus is estimated at about
0.4 MPa, which is softer than ss19 with no salt but stiffer than ds19 with no salt. Here
also there is a local minimum in viscosity with a value of 1.2 mPas, suggesting a highly
hydrated layer. The softest layer, with a shear modulus of 0.3 MPa , is observed at 0.2 M
NaCl – here also we see an average thickness of 6.8 nm, which is only slightly thicker
than the theoretical length, implying that the surface density is not stretching the strands
significantly. Above 0.4 M NaCl the layer condenses and becomes less thick, with
average shear modulus values of 0.35 MPa and viscosity of 2.1 mPas.
The effect of NaCl on ds19 layers is shown in Figure 4.5. The thickness of ds19
layers decreases with increasing NaCl until reaching its minimum of 1.2 nm at 0.6 M
NaCl. Above this concentration the thickness increases again until reaching 3.8 nm at a
concentration of 1 M NaCl. The shear modulus initially decreases at low salt
concentrations and then reaches a maximum at 0.8 M NaCl with a value of 0.7 MPa. The
viscosity decreases slightly at 0.4 and 0.6 M NaCl, but reaches its maximum also at 0.8
M NaCl with a value of 2.6 mPa s.
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4.5.3 Klenow Activity on ss52 Immobilized on QCM-D Sensors
The activity of the Klenow enzyme on immobilized 52 bp DNA with a 39 bp
overhang (ss52) is shown in Figure 4.6. The data are shown as the calculated viscoelastic
parameters over time. The ss52 sequence rapidly binds to the sensor surface. After
washing with Klenow buffer, including free dNTPs, the resultant layer is slightly over 10
nm thick. After the initial peak due to injection of the enzyme, no activity was observed
for about 160 min, except for a small peak at about 380 min. Then, significant activity
was observed for about 150 min. The activity ceased, and presumably the enzyme
disassociated, before the final wash. The final values showed a layer thickness of about
16 nm, a shear modulus of < 0.1 MPa, and a viscosity of about 1.6 mPa s. This thickness
is equivalent to about 85% of the theoretical strand length. The shear modulus is lower
than results for ss19 DNA, indicating that the longer DNA presents a softer polymer.
Additionally, the viscosity is in the range of 1.5 mPas seen for all other sequences thus
far.
4.5.4 ssDNA and dsDNA Binding to Gold Nanoparticles
Both ss19 and ds19 oligonucleotides were self-assembled on 15 nm gold
nanoparticles and salt-aged to NaCl concentration from 0 to 1 M. Resultant
hydrodynamic particle diameter as measured by DLS is shown in Figure 4.7. Unmodified
AuNPs showed an average diameter of 18.4 nm. AuNP-ss19, with the DNA bound
without NaCl (0.0 M), resulted in an average diameter of 23.2 nm. This indicates that the
ss19 layer on either side contributes only 2.4 nm of diameter to the particle, which is
about 37% of the theoretical length of the strand, suggesting that the immobilized layer is
folded to a significant degree about the nanoparticle surface. When binding ss19 in the
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presence of NaCl, all concentrations showed nearly identical DLS profiles with an
average diameter of 32.4 nm. In this case, the salt-aged ss19 layer on each side
contributes 7 nm to the total particle diameter. This is about 0.5 nm longer than the
theoretical strand length, implying that the ssDNA is slightly stretched.
AuNP-ds19 bound without NaCl results in nanoparticles with an average diameter
of 36.4 nm. This implies a total contribution of 9 nm for each ds19 molecules, which is
about 39% longer than the theoretical strand length. For dsDNA, this is surprising since it
is much less capable of uncoiling and stretching compared to ssDNA. However, the
increased averaged diameter is likely due to the wide peak which stretches over diameters
of 100 nm, suggesting some particles are aggregating together and increasing the average
diameter. Adding NaCl exacerbates this phenomenon, with the DLS profiles further
stretching to larger particle diameters and subsequently raising the average diameter.
Above 0.4 M NaCl, AuNP-ds19 particles aggregate irreversibly. Thus, it appears that
ds19 lies upright on the particle surface but there are some unknown particle-particle
interactions that result in aggregation, especially with the addition of salt.
4.5.5 Klenow Activity on DNA-AuNPs
The dynamic activity of the Klenow enzyme on ss52-AuNPs is shown in Figure
4.8. The addition of free nucleotides onto the 39 bp overhangs of ss52 are validated via
observation of a mobility shift in the gel. The addition of the enzyme causes the particles
to migrate more slowly through the gel as soon as one minute after mixing. The rate of
mass addition increases for the first hour, where the total mass added begins to plateau.
At 120 min, the activity has completely leveled stopped.

67

4.6 Discussion
Single stranded and double stranded DNA have significantly different mechanical
properties and thus form distinct architectures when immobilized on surfaces. This
difference is expressed in the persistence length of the oligonucleotides, which is less
than 2 nm for ssDNA but around 50 nm for dsDNA.242 In other word, ssDNA
oligonucleotides of only 10 bp are flexible enough to form tight hairpins and loose,
looping structures,243 while dsDNA oligonucleotides of up to 150 bp act like rigid rods
end tethered to the gold surface.244 Additionally, oligonucleotides can interact with the
gold surface via electrostatic interactions of the exposed nucleobases. This interaction is
enhanced for ssDNA but is also observed for flat-oriented dsDNA oligonucleotides, and
thus can explain why we observe layer thicknesses as low as 1.1 nm. Additionally,
viscosity stays relatively constant, due in part to DNA having an intrinsic viscosity in the
range of 1.5 to 2 mPas, and shear modulus varies between 0.1 and 0.7 MPa.
Polyelectrolyte polymers on surfaces form structures that can be sensitive to the
ionic strength of the solution it is in. Thus, high concentrations of the polymer in solution
may affect how the polymer organizes itself on the surface after immobilization. Indeed,
previous work with proteins and cationic cubosomes have shown that increasing the
concentration in solution above a certain point will actually start to decrease the total
thickness of the immobilized layer, suggesting a structural change due to the higher
solution concentration.245,246 We see this behavior in two different ways from observing
Figures 4.2 and 4.3. For ss19 (Figure 4.2), the viscoelastic properties of the layer vary
non-monotonically with the solution concentration of oligonucleotides. Indeed, at the
lowest concentration of 0.3 µM the layer appears to be the most organized, with rapid
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binding kinetics and an average thickness closest to the theoretical strand length.
Increasing the solution concentration leads to thinner layers, presumably due to the
flattening of the immobilized DNA which can bind electrostatically to the gold via free
nucleobases. The thickness actually increases at certain concentrations, e.g. at 2 and 4
µM, which occurs for unknown reasons but may be due to disorganized layer formation
and a mixture of upright and flat strands. The ss19 layers also become softer and less
viscous, on average, as the concentration increases, indicating a soft, hydrated film,
which contrasts with the parallel, brush like film observed at the lowest concentration.
Adding NaCl to the ss19 films will increase the surface density of bound ss19 strands,
which upon washing reveals an increase in layer thickness as immobilized
oligonucleotides are forced to stand upright or, in the case of 0.4M NaCl, stretch (Figure
4.4). Addition of NaCl causes ss19 layers to become slightly softer compared to the layer
bound in water, likely due to the reduction in folded interactions with the gold surface.
Viscosity increases as NaCl increases, although it reaches a minimum at 0.4 M NaCl
when the layer is at its thickest. Therefore, binding ss19 DNA at a low concentration
leads to a more organized, upright monolayer that is affected when the oligonucleotide
concentration in solution is increased. When adding NaCl, and increasing the surface
density of oligonucleotides, the individual strands become forced to stand upright and
eventually stretch due to the negative repulsion from neighboring strands. At NaCl
concentrations above 0.4 M NaCl, DNA is likely to condense significantly, so the
structures of these layers are likely unorganized and form largely condensed and tortuous
DNA networks.247,248
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The ds19 layers shows substantially different binding kinetics. With increasing
concentrations, the layer thickness decreases linearly (Figure 4.3). In this case, the
dsDNA is similarly influenced by the oligonucleotide concentration in solution, but the
rigidity of the dsDNA results in the formation of a more homogenous structure even
when flattened. We again see that the layer becomes softer as the concentration is
increased, indicating that an organized DNA polymer brush forms a more rigid
monolayer compared to the flat layer. Viscosity does not change to any substantial degree
when adding ds19 at different concentrations. In contrast to ss19, when adding NaCl the
ds19 layer becomes less thick, likely due to the over-coiling of the DNA double helix.
Additionally, even after washing, this coiling might be trapping NaCl and screening the
negative charges on neighboring strands. At concentration above 0.6 M NaCl, the
thickness begins to increase again. Additionally, at 0.8 M NaCl the peak in shear
modulus and viscosity reveals some structural change occurring within the layer. It has
been shown that inducing bends in a DNA duplex will increase the viscosity of the
molecules.249 As such, around 0.8 M NaCl we may be observing a bending of the DNA
double helix, a behavior that could not occur without the salt acting as a condensing
agent. Overall, the rigid structure of the dsDNA alters the way in which the DNA layer is
flattened and also affects the influence of NaCl compared to ssDNA.
The resultant diameter of DNA-AuNPs also reveal some differences between the
binding of ss- and ds-DNA. In both cases, immobilizing oligonucleotides to 15 nm gold
nanoparticles with no salt results in the smallest particle diameter, reaching 23.2 nm and
36.4 nm respectively. For ss19 DNA, this indicates DNA folded about the gold surface.
For ds19 DNA, this diameter is larger than the theoretical diameter, although evidence of
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particle aggregation is present, presumably due to interactions between duplexes
contacting in solution or due to increased contact of Au surfaces due to the lack of
oligonucleotide folding. When salt-aging ss19-AuNPs a maximum diameter is reached of
about 32.4 nm for all NaCl concentration, indicating that on AuNPs no further structural
changes are occurring. A diameter of 32.4 nm is equivalent to a 7 nm increase on each
side due to oligonucleotide binding, which is about 0.5 nm longer than the theoretical
length. When salt-aging dsDNA-AuNPs, a smaller increase in average diameter is
observed while the polydispersity grows, indicating more frequent particle aggregation.
Indeed, above concentrations of 0.4 M NaCl particles in solution would irreversibly
aggregate. Therefore, it is assumed that salt-aging dsDNA-AuNPs leads to increased
inter-particle interactions, likely due to the organized, upright dsDNA layer and the
increased coiling which reduces the electrostatic stabilization effect the DNA would have
on the surface of AuNPs. For ssDNA-AuNPs, the inherent flexibility and smaller
diameter of single stranded oligonucleotides instead leads to more densely packed
monolayers that increase electrostatic stabilization and lead to a stretching of the DNA
layer when resuspending in low ionic solutions.
Comparisons of Klenow activity on both planar gold and 15 nm AuNPs
emphasizes the effect of surface curvature on the structure of the DNA layer. Previous
work investigating Klenow activity on QCM-D used streptavidin/biotin interactions to
produce well-spaced, organized DNA monolayers.250 By binding the DNA directly to
gold, we have a much denser DNA layer and thus the penetration of the enzyme is
affected. The introduction of the enzyme to the DNA layer on QCM-D shows a clear
response upon injection but no significant change is observed for about 160 min. After
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this, an increase in activity occurs and lasts for about 150 minutes and can be seen in
Figure 4.6. This activity is presumably the enzyme finally reaching the terminal ends of
the immobilized DNA molecules to bind and begin filling in the overhang of the ss52
sequence. After 150 minutes the activity suddenly stops, likely due to the enzyme
finishing its repair of the overhang DNA and disassociating. The end result of this
activity is an increase in layer thickness of about 6 nm, a miniscule increase in layer
rigidity, and an increase in the viscosity of the monolayer.
On DNA-AuNPs, the activity of the Klenow enzyme is much more rapid. By
measuring the addition of mass via mobility through an agarose gel, it is seen that the
enzyme begins to work in only a few minutes. The addition of mass stops after only 120
mins, after which a series of degraded products can be observed in the gel (Figure 4.8).
This increase in the speed of enzymatic activity is attribute to the highly curved AuNP
surface which increases the angle of deflection between neighboring DNA strands and
therefore allows the enzyme to penetrate more easily. These results are significant
regarding the enzymatic stability of these nanocarriers in physiological media.
4.7 Conclusions
The properties of spherical nucleic acids (SNAs) described in Chapter 2 suggest
that these nanoparticle structures will play a significant role in formulating advanced and
personalized nanomedicines. Exposure to physiological conditions can significantly
affect the properties of biohybrid particles including structural and mechanical properties,
elasticity, hydrophilicity, swelling, and degradation.251–253 Clinically, this can lead to loss
of biocompatibility, degradation, non-delivery of payloads, or reductions in the
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performance. Thus, it is imperative to understand the unique properties of DNA
monolayers on gold surfaces in physiological environments.
Nucleic acids are a unique polymer in which sequence, length, immobilization
strategy, and state of hybridization can significantly affect structures and mechanical
properties. On gold surfaces, ssDNA acts as a flexible chain capable of folding, coiling,
looping, or adhering to the surface, and dsDNA acts as a rigid rod capable of standing
upright or lying flat.254 Addition of salt can screen negative charges and induce high
density packing of ssDNA, which at sufficient densities can actually cause stretching of
oligonucleotides. For dsDNA, the salt induces supercoiling of DNA double helixes and at
high enough concentrations can induce strand bending. Additionally, the longer
sequences present a much softer layer compared to the shorter sequences as revealed by
the estimations of shear modulus. Thus, increasing the length of the oligonucleotide layer
provides a thicker polymer network and a more mechanically deformable layer, which
has implications for the tuning of nanocarrier properties in the future.
The structure of NA polymer layers is significantly affected by the curvature of
the immobilizing surface. For example, the density of immobilized NAs increases
exponentially as the size of AuNPs is reduced from 200 nm to 2 nm due to the extreme
curvature inhibiting the electrostatic repulsion from neighboring strands.255 We see here
that this curvature also affects the activity of enzymes in penetrating the NA layer. On
planar gold surfaces, the activity of the Klenow enzyme was delayed for over 2 h before
polymerization began; in contrast, polymerization began almost immediately on DNAAuNPs. This improved enzymatic access to the terminal ends of the immobilized
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oligonucleotides holds great significance on the in vivo stability of administered NA
nanocarriers.
The results in this chapter showed furthermore that the nanoarchitectures of NA
layers on gold can be manipulated. By binding in low concentrations of salt and low NA
concentrations, the induction of a folded NA layer is possible. Additionally, by
immobilizing dsDNA or by salt-aging the ssDNA, the layer can be manipulated to stand
upright in a brush formation. It was then questioned whether or not this manipulation
could be exploited for controlled drug release. In the next chapter, it is shown that by
directly manipulating the nanoarchitectures of DNA monolayers on 15 nm AuNPs the
transport of a surface bound drug through the DNA polymer layer can be controlled.
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A

B

Figure 4.1. Typical QCM-D data generation. (A) Frequency and dissipation data at
multiple overtones of a QCM-D sensors is shown oscillating in water over 3 hours. Over
three hours the total frequency drift is less than 0.1 Hz and the dissipation drift is less
than 0.04, indicating excellent stability. (B) A typical loading of a thiolated DNA
monomer is shown for f (blue, bottom) and D (red, top). The binding of the DNA
causes a decrease in frequency and an increase in dissipation. After washing with buffer,
unbound material is removed and the final values are attained.
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Figure 4.2. Modeled parameters of ss19 DNA bound to gold QCM-D sensors at
increasing concentrations. Applying the Voigt viscoelastic model to QCM-D data reveals
estimates of monolayer thickness, shear modulus, and viscosity. Significant differences
are indicated by an asterisk (p-value < 0.05).
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Figure 4.3. Modeled parameters of ds19 DNA bound to gold QCM-D sensors at
increasing concentrations. Applying the Voigt viscoelastic model to QCM-D data reveals
estimates of monolayer thickness, shear modulus, and viscosity. Significant differences
are indicated by an asterisk (p-value < 0.05).
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Figure 4.4. Modeled parameters of ss19 DNA bound to gold QCM-D sensors at 0.3 µM
with increasing concentrations of NaCl. Applying the Voigt viscoelastic model to QCMD data reveals estimates of monolayer thickness, shear modulus, and viscosity.
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Figure 4.5. Modeled parameters of ds19 DNA bound to gold QCM-D sensors at 0.3 µM
with increasing concentrations of NaCl. Applying the Voigt viscoelastic model to QCMD data reveals estimates of monolayer thickness, shear modulus, and viscosity.
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Figure 4.6. Klenow enzyme activity on DNA sequences with single-stranded overhangs
on planar gold QCM-D sensor. DNA was immobilized and then unbound material was
washed with Klenow reaction buffer. A spike in thickness is seen when the enzyme was
injected, but no further activity was observed until about 460 minutes. The activity ceases
before the final wash occurred.
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A

B

Figure 4.7. DLS results for the hydrodynamic diameter of DNA-AuNPs salt-aged to
increasing concentrations of NaCl. Here ss19-AuNPs (A) and ds19-AuNPs (B) are
shown. Unmodified AuNPs are shown as a solid black line. The legend indicates the final
NaCl concentration during salt-aging. The ds19-AuNPs aggregated irreversibly at
concentrations above 0.4 M.
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Figure 4.8. Klenow enzyme activity on DNA sequences with single-stranded overhangs
on 15 nm AuNPs. Results are shown as mobility through a 2% agarose gel. AuNPs are
visible in agarose to the naked eye and here contrast is increased slightly. Mass is added
by the enzyme almost immediately and continues until about 60 min. After 120 min a
series of degraded products are observable in the gel.
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Table 4.1
DNA Sequences
Sequence 5’→3’

Complement 3’→5’

ss19 TTTTATGGTTTACAATATT

N/A

ds19 TTTTATGGTTTACAATATT

CCAAATGTTATAA

ss52 TTTTATGGTTTACAATATT

CCAAATGTTATAAAGCAGCAGCAGCA
GCAGCAGCAGCAGCAGCAGCAGCAGC
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Chapter 5
Tailored Nucleic Acid Architectures at Gold Surfaces for Controlled Therapeutic
Release
5.1 Introduction
Nanoparticle drug delivery systems emerged out of a need for more effective
ways of administering drugs to treat disease.256 The precision of nanotechnology allows
for construction of tailorable therapeutic vehicles, or nanocarriers, with highly
controllable physiochemical properties. This control has resulted in positive treatment
outcomes for many diseases including cancer due to the improved pharmacokinetics and
pharmacodynamics of nanocarriers compared to drug alone.23,257,258 The surface
morphology of nanocarriers play significant role in the controlled delivery of
therapeutics. For non-covalently bound drugs, the release occurs due to the diffusion
gradient of drug molecules away from the nanocarrier and into the bulk solution.259 The
variables that affect drug release include a number of physiochemical properties such as
material chemistry, surface roughness, uniformity, hydrophobicity, and interactions with
therapeutic molecules.260–262
Nucleic acids are attractive nanomaterials due to their ease of controllable
assembly, unique mechanical properties, stimuli responsiveness, and ability to deliver
drug payloads.263 Furthermore, nucleic acids can be used as building blocks for highly
advanced, smart nanocarrier systems making them desirable in the creation of
personalized therapeutics.264–266 There are a number of ways to modulate DNA-based
polymers for therapeutic release. For example, our work with DNA-capped gold
nanoparticles (AuNPs) revealed controllable drug release from DNA layers via affinity
modulation.232,267 Unfortunately, the nanoscale architectures of DNA oligonucleotides at
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surfaces are not well understood.268,269 Single-stranded oligonucleotides (ssDNA) are a
highly flexible polyelectrolyte biopolymer with a persistence length of only a few
nanometers, while double-stranded oligonucleotides (dsDNA) are much more rigid with a
persistence length of 50 nm.242,270 This means that ssDNA may be folded over length
scales of <10 nucleotides (nt) while dsDNA will remain rigid for up to 150 base pairs
(bp). The differences in DNA molecule flexibility have been observed on surfaces under
an applied electric field, where ssDNA is pulled to the surface segment by segment while
dsDNA is flattened as a rigid rod.254 When either covalently or noncovalently tethered to
AuNPs, ssDNA can become folded and interact with the gold surface via exposed
nucleobases or oriented perpendicular to the surface, with high binding densities leading
to stretched layers of parallel oriented ssDNA due to the high concentration of negative
charge.271–273 On the other hand, rigid dsDNA oligonucleotides bind in an organized
fashion and maintain conformational integrity on surfaces.274
Conformational changes of oligonucleotide layers can be exploited to achieve
controllable drug release. On surfaces, nucleic acids can act as physical boundaries to the
free diffusion of drug molecules, via a mechanism known as DNA-gated release. By
capping the pores of porous nanoparticles with dsDNA, release of encapsulated drug by
degradation of DNA duplexes can be triggered by temperature,163,275–277 pH,278,279 nearinfrared light,280,281 target recognition,282 nucleases,275 or UV light.283 Taking into account
our previous work and the multiple biological and medical applications of AuNP-DNA
conjugates,284 we hypothesized that a DNA-gated release could be achieved by
modulating the surface architecture of DNA layers on 15 nm AuNPs. Dexamethasone
(DXM) is a long-acting synthetic glucocorticoid steroid used to treat a number of
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diseases due to its anti-inflammatory and immunosuppressive properties.285–287 Recently
it has been demonstrated that DXM can electrostatically interact with AuNPs via the
fluorine atom and that the presence of negatively charged ligands (e.g. sodium 3mercapto-1-propanesulfonate, or 3MPS) can slow the release of the drug from the AuNP
surface.288,289 In this study, we investigated the ability to sustain the release of DXM from
novel nucleic acid nanoparticles via manipulation of the nucleic acid surface layer
architecture to produce a DNA-gated controlled release mechanism without the need for
triggered DNA degradation. Nucleic acid layers on planar gold surfaces and 15 nm
AuNPs were assessed via quartz crystal microbalance with dissipation (QCM-D) and
dynamic light scattering (DLS), respectively. We then compared the release of DXM
from AuNP-DNA particles synthesized with DNA layers of varying architecture.
5.2 Materials and Methods
5.2.1 Materials
All DNA oligonucleotides were synthesized by IDT (Coralville, IA). Their
sequences are listed in Table 5.1. Gold nanoparticles of 15 nm diameter were purchased
from Ted Pella, Inc (Redding, CA). Dialysis tubes (MWCO 6-8 kDa) were from
Millipore Sigma (Burlington, MA). Dexamethasone (DXM), PBS, NaCl, and all other
reagents were obtained from VWR (Radnor, PA).
5.2.2 Preparation of Thiolated Oligonucleotides
Thiolated oligonucleotides were shipped lyophilized in their oxidized form and
must be reduced before use. Oligonucleotide stocks were prepared in TE buffer (10 mM
Tris-HCl, pH8.0 and 1 mM EDTA) at a 1 mM concentration. Stock solutions were mixed
with 50 mM DTT in phosphate buffer (0.2 M, pH 7.4) for 3 hours. The reduced DNA
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mixtures were desalted using NAP-10 gravity-flow sephadex columns. Concentration of
DNA preparations was validated by their UV absorbance at 260 nm wavelength. All
reduced DNA solutions were brought to working concentrations using deionized water.
The hybridized dsDNA molecules were prepared by mixing equimolar amounts of each
oligonucleotide and its complement at 80oC for 10 min followed by slow cooling to room
temperature.
5.2.3 Preparing Gold QCM-D Sensors
The following cleaning procedure was performed on gold-coated quartz sensors
upon their receipt and immediately after each experiment: sensors and all tubing were
thoroughly rinsed with 0.01% SDS. Then, sensors were cleaned in a UV/ozone chamber
for 10 min, immersed in a base piranha solution (5:1:1 v/v water, H2O2 (30%), NH4OH
(30%)) at 75oC for 5 min, dried using N2, and cleaned again in a UZ/ozone chamber for
10 min. Baseline frequency and dissipation measurements were observed in air and water
before starting experiments.
5.2.4 DNA Immobilization on QCM-D Sensors
Gold sensors were equilibrated in water at room temperature. DNA samples were
injected into the QCMD chamber using a disposable 1 mL syringe. Injections were done
slowly over the course of about one minute to avoid any pressure related effects. For
experiments involving salt, NaCl was mixed with oligonucleotides immediately before
injection into the chamber. The samples were allowed to equilibrate for at least one hour
before washing with 1 mL of water.
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5.2.5 Viscoelastic Modeling
Data modeling was performed using the QTools software package included with
the instrument (Q-Sense Analyzer, Biolin Scientific). In QTools, the ∆f and ∆D data are
related to viscoelastic properties of the DNA layers using a Kelvin-Voigt model
according to the research of Voinova et al.241 The following equations were used:
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where ρ0 and h0 are the density and thickness of the crystal, η3 is the viscosity of the bulk
liquid, δ3 is the viscous penetration depth of the shear wave in the bulk liquid, and ρ3 is
the density of liquid, and ω is the angular frequency of the oscillation. The adsorbed
DNA layer is characterized by density (ρ1), viscosity (η1), shear elasticity (μ1), and
thickness (δ1). Before each experiment, the instrument was baselined and washed with
pure water, giving a fluid viscosity of 0.001 kg/m3 and fluid density of 1000 kg/m3. The
effective density of the DNA was assumed to be 1.06 g/cm3.290
5.2.6 Preparation of Nanocarriers
Nanocarriers were prepared by mixing 50 µL of reduced, thiolated DNA stock (4
µM) with 1 mL of 15 nm AuNPs (1.4x1014 particles/mL) overnight. The mixture was
then brought to 50 mM phosphate using 2M phosphate buffer. Salt-aging was done by
slowly adding a 5 M NaCl solution drop wise over the course of a few hours to the final
concentration of 0.4 M NaCl. Nanocarriers were centrifuged for 30 min at 13,200 rpm,
three times, and resuspended in PBS. The final product was characterized via DLS using
a Malvern ZS90 Nano series zetasizer at 25oC with an AuNP concentration of 4.7 x 1012
particles/mL.
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5.2.7 Drug Loading and Release
We mixed nanocarriers with DXM (1 mg/mL in 50% ethanol) at a weight ratio of
5:1 Au:DXM and vortexed for 4 hours, according to previous studies.288,289 Nanocarriers
were washed three times with PBS, recovered by centrifugation and resuspended in 0.01
M PBS. AuNP concentration was determined via absorbance at 520 nm. Equivalent
concentrations of DXM loaded nanocarriers were aliquoted into dialysis membrane tubes
and submerged in PBS at 37oC. Aliquots of release media were collected and DXM was
detected by measuring UV absorbance at 241 nm and comparing to a standard curve.
Cumulative release percentage was calculated using the ratio of DXM mass released at
time t and the total DXM mass released over the course of the experiment (Mt/M∞).
5.2.8 Statistical Analysis
Best fit lines of drug release data were obtained by modeling as a first order
release. Statistical significance was calculated via Student’s t-test with a p-value of <
0.05 considered significant. All data are shown as averages +/- standard deviation.
5.3 Results
Oligonucleotides were first immobilized on gold QCM-D sensors to estimate layer
thickness. Observed energy dissipation from the bound layer prevents accurate
calculation of bound mass via the Sauerbrey equation, and thus the Kelvin-Voigt model
was necessary to estimate thickness. Note that for modeling purposes we assumed
constant density of the DNA layer in all experiments. The thickness of ss19 and ds19
monolayers, including a ss19 bound in the presence of 0.4 M NaCl, on gold surfaces is
shown in Figure 5.1. In our earlier studies we found that maximum DNA loading on
AuNPs is achieved at a DNA concentration of 4 µM and 0.4 M NaCl.232 On QCM-D
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sensors, ss19 layers and ss19 layers bound in 0.4 M NaCl resulted in layer thicknesses of
4.5±2.5 nm and 7.5±1.63 nm, respectively, which is equivalent to 69% and 115%,
respectively, of the theoretical sequence length. For ds19 bound without salt we see and
average layer thickness of 5.5±0.2 nm, which is equivalent to 85% of the theoretical
strand length. The effect of hybridization was also investigated using longer, 52 bp
sequences. These results on QCM-D are shown in Figure 5.2. The ss52 strand forms a
layer with thickness of 4.6±2.5 nm. This observation suggests that over 75% of the
ssDNA strand is folded over onto the gold surface. Sequence ds52 however forms a layer
of 18 nm, equivalent to 91% of the theoretical sequence length. Thus, ssDNA
immobilized without the presence of salt forms a highly folded monolayer on the gold
surface.
DLS profiles of the hydrodynamic particle diameter of 15 nm AuNPs conjugated
to ss19 and ds19 oligonucleotides is show in Figure 5.3. Since the particles formed are
spherical, this represents an accurate estimation of particle size. Additionally, the
presence of particle aggregation can be confirmed or denied via observation of
absorbance profiles around a wavelength of 520 nm for a 15 nm AuNP. Thus, the
changes in diameter observed here represent only addition of spherical NA monolayers.
Unmodified AuNPs showed an average diameter of 18.4 nm, with a relatively
sharp peak indicating a highly monodisperse sample. Conjugation of DNA induces an
increase in diameter with a simultaneous increase in polydispersity. AuNP-ss19 with no
NaCl had an average diameter of 23.2 nm, suggesting the ss19 layer on either side only
contributes 2.45 nm, which is 38% of the theoretical sequence length. This result implies
that the ss19 molecules are highly folded about the AuNP surface. AuNP-ss19 (0.4M
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NaCl) and AuNP-ds19 show similar results to each other, with average diameters of 32.4
nm and 36.4 nm, respectively. This is equivalent to a single oligonucleotide contribution
of 7 nm and 9 nm, respectively, or 108% and 138% of the theoretical sequence length.
We observe here that the AuNP-ss19 salt-aged to 0.4 M NaCl again cause the
immobilized sequences to stretch longer than their theoretical length. The AuNP-ds19
layer appears to be even more greatly stretched, which is unexpected; however, the DLS
profile also indicates higher polydispersity which may be increasing the average diameter
estimate.
The hydrodynamic diameter of AuNPs conjugated with ss52 or ds52
oligonucleotides is shown in Figure 5.4. AuNP-ss52 forms with an average diameter of
34.5nm, which is larger than AuNP-ss19 (23.2 nm) but smaller than AuNP-ds19 (36.4
nm). This indicates a contribution from ss52 oligonucleotides of 8.1 nm, or less than half
of the total strand length, suggesting a significant amount of oligonucleotide folding.
AuNP-ds52 forms a particle of average diameter 74.5nm, which suggests an
oligonucleotide layer thickness 150% of the theoretical size. However, we again see an
increase in polydispersity with these particles which skews the average. A large fraction
of particles do match the theoretical diameter of 57.8nm. Therefore, we see a significant
amount of folding within DNA monolayers formed with ssDNA while layers formed with
dsDNA - or salt-aged ssDNA - present a much more organized, upright-oriented layer.
We then investigated the influence that these distinct DNA layer structures had on
the release of a surface bound drug. The results for DXM release from AuNP-ss19,
formed in either 0 or 0.4 M NaCl, and AuNP-ds19 into PBS at 37oC are shown in Figure
5.5. Calculated release rate constants are given in Table 5.2. AuNP-ss19, bound without
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salt, releases DXM at the slowest rate and continues to release the drug for 192 h with a
release rate constant k = 0.014 (R2 = 0.99). When salt-aged to 0.4M NaCl, where the ss19
showed evidence that the layer was upright and even stretched, the release rate is fastest
with complete fractional release reached in about 96 h and a rate constant k = 0.157 (R2 =
0.97). The release rate for AuNP-ds19 is only slightly lower than that of AuNP-ss19 in
0.4 M NaCl. AuNP-ds19 releases DXM for between 96-120 h with a release rate constant
k = 0.138 (R2 = 0.94).
The release of DXM from AuNPs conjugated with 52 bp DNA sequences are
shown in Figure 5.6. Calculated release rate constants are given in Table 5.2. AuNP-ds52
releases all of the bound drug in about 600 h with release rate constant k = 0.004 (R2 =
0.97), while AuNP-ss52 continues to release for about 800 h with release rate constant k
= 0.002 (R2 = 0.97). The difference in release rates between 19 and 52 bp sequences
(Figure 5.5 and 5.6, respectively) is striking, with nearly a 4-fold reduction in release
rate. Additionally, the magnitude of changes in release rate between ssDNA and dsDNA
are different at length scales of 19bp and 52 bp. The release rate of DXM from AuNPds19 is almost 10-fold greater than that of AuNP-ss19. However, for AuNP-ds52 it is
only twice as fast compared to AuNP-ss52. Thus, the effect of inducing an upright NA
orientation has lees of an influence on drug release rate as the thickness of the layer
increases.
5.4 Discussion
This work shows that the transport of a surface-bound drug through a DNA
monolayer conjugated to an AuNP can be controlled via manipulation of the size and
structure of the DNA layer (Figure 5.7). The DNA layer structures were validated using
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QCM-D and DLS. The utilization of QCM-D allows one to determine the structure of a
polymer film in situ by modeling viscoelastic parameters from the frequency and
dissipation data. To do this, we had to assume a constant density of the DNA polymer. It
is known that the true density of the layer must lie somewhere between that of water and
the density of pure DNA (1.43-1.7 g/cm3).291 On 15 nm AuNPs under optimized
conditions, short oligonucleotides were found to bind at a maximum of about 1.4x1013
molecules/cm2,232 while optimized binding of duplexes on planar surfaces resulted in
about 3.4x1012 molecules/cm2.274 Previous reports utilizing QCM-D and SPR found that
the grafting density of oligonucleotide layers was approximately 1.06 g/cm3,290 which
would agree with surface density in the range of 1-3 (x1012) molecules/cm2. Therefore,
this density value (1.06 g/cm3) was utilized for all Kelvin-Voigt modeling in this work.
A perfectly organized, upright monolayer of DNA should produce an estimate
thickness approaching the theoretical length of the sequence. Additionally, an upright
sequence should have an identical thickness whether it is ssDNA or dsDNA. On QCM-D,
in all cases the thickness of the layer was less than the theoretical length. For dsDNA, the
52 bp strand was closer to the theoretical length (91%) than the 19 bp strand (85%). This
may be due to the ability of the shorter strand to lie flat on the gold surface (Figure 4.3),
whereas the longer sequence is unable to lie flat in a similar way. The ss52 sequence,
which is almost 3-fold larger than ss19, results in a layer thickness only marginally larger
than the ss19 layer. This suggests that a large majority of the sequence is folded over the
gold surface. Since this is a larger sequence, this represents a highly folded and dense
network of DNA. The ss19 layer bound in 0.4 M NaCl results in an apparent stretching of
the immobilized strands, leading to a thickness greater than the theoretical sequence
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length. Thus, this shows evidence that the salt-aged layer is forming an upright
monolayer similar to that seen with the dsDNA.
DLS experiments on DNA-AuNPs show similar behavior. Both AuNP-ss19 and
AuNP-ss52 show average diameter measurements that are smaller than expected using
the theoretical sequence lengths. Thus, the DNA must be folding about the AuNP surface.
For the AuNP-ss19 salt-aged to 0.4 M NaCl, the resultant diameter indicates DNA
sequences of 7 nm in length, which is larger than the theoretical length and suggests a
stretched monolayer which would be oriented upright. The dsDNA layers both appear
larger than expected from theoretical sequence lengths. This is not likely due to stretching
as dsDNA is unable to stretch beyond a few nanometers. However, a significant increase
in polydispersity is observed form the graphs, and this is likely causing the increase ein
average diameter. For both AuNP-ds19 and AuNP-ds52, a significant fraction of particles
forms around the theoretical diameters.
The mechanism behind 0.4M NaCl achieving maximum DNA loading is as of yet
undetermined. In separate experiments involving salt-aging dsDNA on AuNPs, we found
that concentrations of 0.6M NaCl and above would cause AuNPs to aggregate
irreversibly, presumably due to an extreme coiling of dsDNA duplexes that allows for
AuNP surfaces to come into close contact with one another. We hypothesize that by
electrostatically shielding the negatively charged DNA backbone, increasing NaCl
concentration induces dense packing of DNA up to a critical level after which the DNA is
highly condensed by a high local concentration of positively charged ions. Thus, 0.4M
NaCl may constitute a critical salt concentration for achieving the highest DNA loading
without inducing condensation or aggregation.
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DXM is not an intercalating drug and therefore will not bind directly to DNA.
Therefore, the only mechanism to control the drug transport would be excluded volume
and steric hindrance. This hindrance can occur via both the presence of the DNA chains
in the diffusion path and the presence of negative charges along the DNA backbone (zeta
potential -30mV for similar sized sequences on 15nm AuNPs292), which presents a barrier
significantly larger than the crystal diameter of DNA. Thus, the unique, controllable layer
architectures adopted by ss- and ds-DNA immobilized under certain conditions acts as
the main mechanism for controlled release. Binding the ss19 strand onto gold surfaces in
the absence of salt resulted in monolayers that were lower than the theoretical sequence
length, implying that the DNA adopts a folded orientation. When binding in 0.4M NaCl,
ss19 layers form that are at or slightly larger than our theoretical strand length, suggesting
an upright orientation. This orientation is reflected in the release data, where DXM
releases more quickly from the AuNP-ss19 0.4M NaCl platforms than from AuNP-ss19
formed in the absence of salt (Figure 5.4). The AuNP-ds19 releases drug marginally
slower than AuNP-ss19 0.4 M NaCl; this may in fact be due to the presence of hybridized
duplexes which are upright but still take up more space than ssDNA. Furthermore,
AuNP-ss52 releases drug at an even slower rate, presumably due to the increased folding
the longer ssDNA undergoes on the gold surface (Figure 5.5).
The reduction in release rate observed with increasing DNA sequence length is
likely due to the increase in physical space taken up by the longer molecules and the
subsequent increase in negative charges along the longer DNA backbone, which
continues to hinder the diffusion of the drug and prevents it from entering solution.
AuNP-ss52, having a highly folded or coiled structure, has the slowest release rate of all
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platforms tested, suggesting that this architecture combined with the increased length
slows the release of the drug further. AuNP-ds52, which remains rigid at this length
scale, releases drug more quickly by comparison due to the upright nature of the bound
DNA. However, both sequences at this length release drug more slowly compared to 19
bp sequences, indicating that the length of the sequence affects the release rate regardless
of layer architecture. Notably, the difference in drug release rates between ss- and dsDNA layers is greater for the shorter sequences than it is for the larger sequences,
suggesting a slower relative release rate for dsDNA as the sequence length increases
(Table 5.2). Thus, it appears that at shorter sequence lengths, the effect of DNA
architecture on drug release rate is more prominent. For longer sequences, the increase in
DNA density even with upright layers still appears to slow the release rate of the drug.
5.5 Conclusions
SNA platforms will outperform many DNA nanostructures with regard to drug
delivery and systemic administration, however controlling the release of drugs from such
platforms is difficult. In this work we showed that tailoring nucleic acid architectures on
gold surfaces can be used to achieve controlled, DNA-gated release of bound molecules.
It was shown that the binding of oligonucleotides to gold involves complex binding
behaviors based on the inherent flexibility or rigidity of ss- and ds-DNA. Single-stranded
oligonucleotides at low surface densities are free to randomly coil and fold over onto the
gold surface. We were able to manipulate the surface architecture of DNA
oligonucleotides by immobilizing in the presence of salt or by hybridizing
oligonucleotides to form double-stranded duplexes, both of which appear to encourage
upright, organized DNA monolayers. By conjugating oligonucleotides to AuNPs and
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investigating the layer architecture, it was observed that upright oriented layers allow for
a faster diffusion of the drug into solution. This is presumably due to the physical and
electrostatic barrier the DNA presents to the diffusion drug molecules, which is reduced
with upright oriented architectures. At longer sequence lengths, this effect is less
pronounced. It is hypothesized that as the sequence length increases, the high density of
DNA presents a diffusion barrier even for upright DNA layers.
We investigated DNA sequences of two different lengths, either ssDNA or
dsDNA, and two distinct gold surfaces, planar gold and highly curved 15 nm AuNPs.
Therefore, a wide range of parameters remains unstudied, including the role of surface
curvature in DNA layer architecture and thus the release profiles of the drug.255 A more
thorough application of molecular simulations and mathematical drug release models
would speed up the elucidation of key parameters involved in the controlled release of the
drug.293–296 This approach would lead to optimization of the nanocarriers for drug
delivery. Additionally, the potential for triggering the release of drug via introduction of
complementary sequences to ssDNA layers presents a very interesting concept. Such
approaches highlight the potential of this novel controlled release mechanism.
We used DXM as a template molecule owing to its electrostatic interaction with
the gold surface. As such we expect that this platform could be extended for the sustained
release of a wide variety of molecules, including other fluorinated corticosteroids or
surface bound therapeutics, including proteins.297 The programmable nature of DNA
nanostructures also provides an avenue toward selective targeting or triggered release
mechanisms, adding to the multifunctionality of this nanocarrier. In the future, we
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envision highly effective dual release nanocarriers that have sustained release from
intercalated and surface bound therapeutics using a single, personalized platform.
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Figure 5.1. Thickness of 19 bp DNA layers on planar gold sensors. The theoretical
sequence length is 6.5 nm. The ss19 and ds19 layers are less thick than the theoretical
length; in the case of ss19, it is 2 nm less than expected, suggesting some oligonucleotide
folding. For ss19 salt-aged to 0.4 M NaCl, the layer appears larger than the theoretical
length, indicating a stretched oligonucleotide layer. Significant differences are indicated
by an asterisk (p-value < 0.05).
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Figure 5.2. Thickness of 52 bp DNA layers on planar gold sensors. The theoretical
sequence length is 19.7 nm. The ds52 sequence forms slightly under this length,
suggesting an upright monolayer. The ss52 sequence, however, appears to form a highly
folded nucleic acid monolayer. Significant differences are indicated by an asterisk (pvalue < 0.05).
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Figure 5.3. Hydrodynamic diameter of 19 bp DNA-AuNPs. Unmodified AuNP (−),
AuNP-ss19 (), AuNP-ss19 salt-aged to 0.4 M NaCl (), AuNP-ds19 ().
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Figure 5.4. Hydrodynamic diameter of 52 bp DNA-AuNPs. Unmodified AuNP (−),
AuNP-ss52 (), AuNP-ds52 ().
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Figure 5.5. Release of DXM from 19 bp DNA-AuNPs. AuNP-ss19 (), AuNP-ss19 saltaged to 0.4 M NaCl (), AuNP-ds19 ().
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Figure 5.6. Release of DXM from 52 bp DNA-AuNPs. AuNP-ss52 (), AuNP-ds52
().
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Figure 5.7. Schematic representation of a novel mechanism of controlled therapeutic
release. The folded nucleic acid orientation presents a steric and electrostatic hindrance to
drug transport thus slowing the release. An upright orientation, however, allows for a
more rapid release of the drug.
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Table 5.1
DNA Sequences
Sequence 5’→3’

Complement 3’→5’

ss19 TTTTATGGTTTACAATATT

N/A

ds19 TTTTATGGTTTACAATATT

CCAAATGTTATAA

ss52 TTTTATGGTTTACAATATT

CCAAATGTTATAAAGCAGCAGCAGCA
GCAGCAGCAGCAGCAGCAGCAGCAGC
CCAAATGTTATAAAGCAGCAGCAGCA
GCAGCAGCAGCAGCAGCAGCAGCAGC

ds52 TTTTATGGTTTACAATATTTCGTCGTCGT
CGTCGTCGTCGTCGTCGTCGTCGTCGTCG
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Table 5.2
Release Rate Constants
k

R2

AuNP-ss19

0.014

0.99

AuNP-ss19
(0.4M NaCl)

0.157

0.97

AuNP-ds19

0.138

0.94

AuNP-ss52

0.002

0.97

AuNP-ds52

0.004

0.97
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Chapter 6
Near Zero-Order Release of Daunomycin from Engineered Nucleic Acid
Monolayers
6.1 Introduction
Cancer represents a major public health crisis worldwide. Certain cancers, such as
pancreatic, liver, and non-small cell lung cancer, remain extremely deadly while
generally treatable cancers, such as breast cancer, result in significant risk of mortality if
not diagnosed early and allowed to metastasize.1 Many chemotherapeutic drugs have
been developed to target cancerous tissue but they often produce prohibitive side effects.2
Advances in molecular biology and tumor physiology have revealed that a tailored and
personalized approach is capable of significantly improving outcomes for patients.3
Furthermore, driven by the emergence of nanomedicine, delivery systems for drug
combinations have arisen as an exciting strategy for both personalizing treatment and
carrying drugs for targeted delivery to tumor sites.
The tunable properties expressed at the nano-scale have been exploited for the
treatment of many pressing medical issues with varying results.4–6 Cancer in particular
has seen a profound impact due to the development of a variety therapeutic agents
designed with molecular precision for the treatment of specific cancer genotypes.7 Drugs
modified for specific delivery, such as antibody-drug conjugates (ADCs), have grown in
popularity but suffer from small payloads, low avidity of ligand binding, and the
emergence of drug resistance.8–10 Utilizing a nanocarrier for payload delivery, however,
has distinct advantages including diverse payloads, high drug-to-targeting-ligand ratio,
multivalency, and controlled drug release.11 Nanocarriers can be modulated and tailored
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separate from the drug payload for use in a wide variety of applications. Therefore,
rationally designed nanocarriers present an outstanding opportunity for the delivery of
chemotherapeutics.
Nucleic acids provide a very promising molecular platform for the formulation of
next-generation therapeutic nanocarriers. Specific sequence motifs for targeting,
immunomodulation, structural stability, and drug loading can be incorporated into a
modular nanocarrier via the well-known base pairing mechanism.12 Controllable, layerby-layer assembly allows for the formulation of multifunctional nanocarriers tuned to
overcome the multitude of physiological barriers to drug delivery, including in vivo
stability and degradation, tissue localization, immunogenicity, and overcoming multidrug
resistance.13–15 Thus, utilizing nucleic acids as the functional component of nanocarriers
provides significant advantages over presently used strategies. However, one of the
largest barriers to successful administration of nucleic acid nanocarriers is control over
drug release, an essential parameter for highly toxic chemotherapeutics.16,17
Unfortunately, controlling the release of drugs from nanocarriers is a great challenge.18
The mechanisms by which cytotoxic drugs interact with nucleic acids can be
exploited to carry drug payloads, but no research thus far has utilized these mechanisms
to control drug release. The mechanism of action of the drug can effectively be used in
the design of the nanocarrier. Our group has pioneered this biomimetic approach to drug
release using a novel, biohybrid nanocarrier based on thiolated nucleic acids conjugated
to a 15 nm gold nanoparticle (AuNP) and demonstrated controlled release of drugs by
varying binding affinity via sequence modulation.19,20 Furthermore, we recently showed
that the transport of a negatively charged drug bound to the surface of AuNPs can be
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controlled by increasing the degree of folding/coiling of the oligonucleotide layer.21 In
this work, we show for the first time that a biomimetic approach to DNA monolayer
design can be utilized to control the release of an intercalating drug, daunomycin.
Daunomycin intercalates within double-stranded DNA non-covalently via molecular
shape, hydrogen bonding, salt bridging, and van der Waals interactions.22 It binds
preferentially to GC-rich nucleotide sequences, specifically those flanked by an AT base
pair.23 The high-affinity binding sequence is represented by an oligonucleotide
containing multiple AGC motifs (Table 6.1). At the onset of our studies, we hypothesized
that by increasing the thickness of oligonucleotide monolayers we can extend the release
of daunomycin. We investigated this hypothesis by pre-loading DNA duplexes with the
drug and immobilizing them on gold-coated wafers to measure drug release.
Additionally, we compared the release of drug from two distinct sequences conjugated to
AuNPs to determine the effects of shape and curvature of the nanocarrier on drug release.
6.2 Materials and Methods
6.2.1 Materials
Custom DNA oligonucleotides with 5' terminal thiol modifications were
purchased from IDT (Coralville, IA). They consisted of a high-affinity binding sequence
comprised of a nucleotide triplicate motif (AGC) and a random sequence of the same
length (RAN). Each sequence has a 6 nucleotide spacer and a drug binding region
comprised of either 4, 8, or 12 intercalating sites (4X, 8X, and 12X). Gold-coated silicon
wafers with 10mm2 area and 100nm thick gold layers were purchased from Platypus
Technologies (Madison, WI). Daunomycin powder was purchased from VWR (Radnor,
PA). All other reagents were purchased from VWR.
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6.2.2 Drug Loading and Quantification
DNA oligonucleotides at a constant concentration were mixed with molar ratios
of daunomycin from 25-1000 to 1 (drug to DNA) in water overnight on a rocking
platform at room temperature. The fluorescence of the sample was measured on a
Spectramax M3 spectrophotometer (Malvern) with an excitation of 495nm and an
emission of 595nm. DNA-containing samples were compared to equivalent
concentrations of drug without DNA. Since daunomycin will not fluoresce while in
complex with DNA, the calculated difference in total drug concentration represents the
fraction of drug intercalated in DNA oligonucleotides.
6.2.3 Wafer Preparation and DNA Loading
Gold wafers were precleaned in base piranha solution for 5 min at 70oC and dried
under N2. They were then submerged in a solution of drug loaded oligonucleotides at a
concentration of 300nM for one hour at room temperature. The DNA loaded wafers were
rinsed three times with PBS to remove unbound material. They were utilized immediately
for drug release studies after loading.
6.2.4 Drug Release Studies
DNA loaded wafers with intercalated daunomycin were submerged in 3mL of
PBS in a 24-well plate and kept at 37oC during the course of the experiment. At specified
time intervals a sample of release media was taken and measured for the presence of
daunomycin, followed by replacement of fresh PBS in each well. The cumulative release
of drug was plotted over time until no further release was detected. Release data was
converted into a fractional release by calculating the ratio of mass released at each time
point and the total mass released at the end of the experiment (Mt/M∞).
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6.2.5 Drug Release Modeling
The Korsmeyer-Peppas model describes drug release phenomena according to the
following equation:
𝑀𝑡
= 𝑘𝐾𝑃 𝑡 𝑛
𝑀∞
Where Mt/M∞ is the fractional release at time t, kKP is the release rate constant, and n is
the release exponent that provides information about the mechanism of drug release. This
model is appropriate used for values Mt/M∞ < 0.60. A value of n=0.5 describes first-order
release kinetics, values of 0.5 < n < 1 describes anomalous (non-Fickian) diffusion, and
n=1 describes zero-order release.
6.3 Results
We utilized low and high affinity daunomycin binding sequences of DNA across
three different oligonucleotide lengths to control drug release from DNA films on gold
surfaces. The high affinity sequence (AGC) is comprised of a repeating AGC motif
which provides an energetically favored molecular structure for drug intercalation. The
low affinity sequence (RAN) is a random oligonucleotide sequence designed to have a
low GC content. The DNA sequences used in this work are shown in Table 6.1.
Both the RAN and AGC sequences were investigated at three lengths
corresponding to the theoretical amount of drug per oligonucleotide, i.e. 4X, 8X, or 12X
daunomycin molecules per DNA. These designations represent binding regions of 12, 24,
and 36 base pairs in length, respectively, with one drug molecule intercalated at every
three base pairs. The total drug bound to all oligonucleotides according to length is
shown in Figure 6.1. The rate of drug binding increases with an increasing molar ratio of
daunomycin until a plateau around the theoretical limit of intercalation at a molar ratio of
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500:1 drug to DNA. As the DNA sequences get longer, the rate of drug loading increases
more rapidly with increasing amounts of drug. This is due to the positive cooperativity of
daunomycin intercalation along with the greater concentration of binding sites contained
in the longer oligonucleotides. At the highest molar ratios intercalation decreases slightly
for all sequences, which may be attributed to the instability of daunomycin in aqueous
solutions at high concentrations.
All sequences were pre-loaded with daunomycin and immobilized on gold wafers
via 5’-terminal thiol modifications to measure drug release over time. The release
constants are summarized in Table 6.2. Within the length scales used, the investigated
DNA duplexes form organized, upright monolayers with binding densities in the range of
3x1012 oligonucleotides/cm2.21 Therefore, the only variables are the nucleotide sequence
and the thickness of the DNA layer.
The fractional release of daunomycin from RAN sequences over 168 h is shown
in Figure 6.2. After 24 hours, RAN 4X released 68% of the total bound drug and the
release began to plateau at 96 h. The parameter n calculated from equation 1 was 0.572,
indicating an approximate first-order release. By increasing the length of the
oligonucleotide, the release of drug from RAN sequences is extended. Both RAN 8X and
RAN 12X released drug for up to 144 h, with the release constant for RAN 12X being
half of that of 8X. The calculated n for RAN 8X was 0.524, lower than for RAN 4X, and
again approximating first-order kinetics. For RAN 12X, n was 0.606, indicating nonFickian diffusion.
The fractional release of daunomycin from AGC-rich sequences over 336 h is
shown in Figure 6.3. After 24 hours, AGC 4X released 41% of the total bound drug and
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by 96 h had released only 75% of drug. By the end of one week AGC 4X had released
95% of the bound drug. The parameter n for AGC 4X was 0.636, indicating non-Fickian
diffusion and more control over drug transport. Increasing length of AGC extended the
release for 216 and 288 h for AGC 8X and AGC 12X, respectively. Compared to AGC
4X, the release constants are reduced by a factor of 6.1 and 15.3, respectively. AGC 8X
sequence has an n value of 0.864, while AGC 12X has an n value of 0.976, or nearly zero
order.
To further analyze the effects of sequence and length on drug release, the release
rate constants kKP for both sequences were plotted as a function of oligonucleotide length,
corresponding to 4X, 8X, or 12X drug per oligonucleotide. The results are shown in
Figure 6.4. Release rates for RAN sequences are 2.2, 9.6, and 12.3-fold higher than
corresponding AGC sequences for 4X, 8X, and 12X lengths, respectively. RAN release
constants decrease linearly (R2 = 0.998) as the sequence is extended (slope = -0.011). For
sequence AGC, the release rate decreases more rapidly between 4X and 8X (linear slope
= -0.013). The value kKP for all three lengths of AGC follows a power law relationship
(R2 = 1). Thus, increasing the length of AGC above 12X, or 36 bp, is likely to show
diminishing returns regarding drug release.
As drugs are delivered using spherical nanoparticles, curvature of the surface to
which DNA is attached is likely to play a role in release rate. This is due to the increased
surface area to volume ratio at the nanoscale and the resultant substantial increase in
deflection angle between neighboring oligonucleotides.24 To investigate this, we
compared RAN 12X and AGC 12X drug-loaded sequences on 15 nm AuNPs and
measured drug release over 144 h. The results are shown in Figure 6.5. Release rate
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constants are shown in Table 6.2. The release kinetics are strikingly different on AuNPs
compared to planar gold. In this case, the best fit for release kinetics for both sequences is
first-order kinetics (n = 0.43 for spherical particles). AuNP-RAN release all of the drug
payload in 48 h, while AuNP-AGC extends the release for 96 h. Additionally, the release
rate constant of AuNP-AGC is significantly lower than AuNP-RAN (0.304 and 0.401,
respectively).
6.4 Discussion
Nucleic acids have excellent potential for constructing personalizable drug
delivery vehicles but controlling the release of intercalated drugs presents a huge
challenge for researchers. In this work, we were able to achieve improved drug release
kinetics from gold wafers and AuNPs coated with diverse DNA sequences of various
length . On the flat surface of the wafers, we also achieved near constant release of the
drug from a DNA monolayer via sequence and length modulation. However, the release
from the AuNP surface was much more rapid.
The mechanism of daunomycin binding to nucleic acid duplexes has been
described in previous reports.22,23 Insights into the structure of the daunomycin-DNA
complex reveals the likely reason for the sequence specific drug release. The aglycon
chromophore of daunomycin is oriented at a right angle to the long axis of the DNA with
the cyclohexane ring and daunosamine moieties resting in the minor groove, covering
three base pairs. The ratio of one drug per three base pairs is confirmed in Figure 6.1.
Several hydrogen bonds and a bridging sodium ion stabilize the complex. The hydroxyl
group on daunomycin C9 forms two hydrogen bonds with N2 and N3 of the adjacent
guanine. These two hydrogen bonds contribute to the preference of daunomycin for

115

subsequent GC base pairs. Additionally, a flanking AT may be energetically favorable as
well due to the repulsive forces that would arise between the daunosamine and the 2amino group of guanine if a GC pair were substituted.23 Thus, the specific motif of AGC
within oligonucleotide duplexes is energetically favored than the RAN sequence and
results in more extended drug release.
Figures 6.2 and 6.3 illustrate that increasing sequence length leads to more
extended drug release, even for RAN sequences. One driver for this extended release is
the principle of excluded volume. As the drug must diffuse through the polymer before
dissolving in solution, longer DNA oligonucleotides increase the steric restrictions on the
diffusing molecules, keeping them trapped within the polymer layer. Indeed, in low ionic
conditions, the effective diameter of upright oligonucleotides increases substantially
compared to the crystal diameter of DNA.25,26 Additionally, the binding of daunomycin to
DNA duplexes exhibits positive cooperativity at physiological salt concentrations.20,27
Thus, the drug likely intercalates with higher affinity to the longer sequences. This higher
affinity would supplement the excluded volume effect and sustain the release of the drug
for longer periods. In the case of AGC 12X, where sequence specificity, excluded
volume, and cooperative binding all play a part, diffusion of the drug is effectively
controlled.
Additionally, unique intermolecular interactions between the parallel DNA
sequences cannot be discounted.28 Recently it was observed that homologous DNA
sequences can undergo complex intermolecular associations even in physiological salt
concentrations.29 This phenomena may be exacerbated by the dense packing of parallel
DNA on the gold surface. Furthermore, guanine-rich sequences are capable of forming
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inter- and intra-molecular structures such as the G-quadruplex. It has been observed that
daunomycin can interact with G-quadruplex structures and effectively increase the
thermal stability of the complex.30 Thus, for the AGC sequences, the presence of parallel
strand interactions stimulated by the high GC content and the subsequent binding of
daunomycin and complex stabilization may further contribute to the controlled release of
the drug from the DNA layer. The extent to which these intermolecular interactions play
a role, if at all, is unknown.
Finally, the striking differences in release kinetics between oligonucleotide layers
in planar gold and AuNPs must be noted. Daunomycin was released at a rate between 3
and 4-fold faster using sequences attached to AuNPs compared to planar surfaces.
Additionally, AuNPs show concentration based, first-order release kinetics as opposed to
the controlled transport exhibited by the planar monolayers. Indeed, even for small
oligonucleotides, the surface curvature of AuNPs has significant effects on the deflection
angle between adjacent molecules.24 This curvature has significant implications for
properties such as surface ligand structure, surface solvation, and flow dynamics.31–33 Our
experiments clearly demonstrate that the curvature increases the rate of drug release. It is
likely that the increased curvature on the nanoparticle surface significantly reduces the
intermolecular interactions between parallel-oriented DNA strands and the probability of
re-binding of the drug to DNA strands with free intercalation sites. Thus, transport from
the layer cannot be controlled precisely and dissociated drug is quick to dissolve in the
release media.
Spherical nucleic acid nanocarriers, such as those constructed on AuNPs in this
work, have gained great interest for their stability in vivo and ability to be internalized
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into cells.34 To date, they have been used mainly as agents for delivering RNAs rather
than as nanocarriers for chemotherapeutics drugs. More recently, a first-in-human phase
0 clinical study of RNA interference–based spherical nucleic acids has commenced to
treat patients with recurrent glioblastoma.35 The principles of design for nucleic acid
nanocarriers may require a different strategy. Fortunately, nucleic acids provide a toolkit
for the facile production of unique nanoarchitectures based on specific angles to create
distinct molecular shapes and tunable physiochemical properties.36–38 As such, the
investigation of nanostructures with flat surfaces, such as polyhedra, or at least larger
aspect ratios, such as nanorods, may provide both the advantages of spherical nucleic
acid architecture with the advantages of planar nucleic acid layers for extending drug
release.
6.5 Conclusions
In conclusion, this work shows for the first time near zero-order release of an
intercalating drug from an engineered DNA monolayer via biomimetically exploiting the
binding mechanism of the drug to nucleic acids. This was achieved by modulating the
nucleotide sequence and length of a drug loaded DNA oligonucleotide to take advantage
of the sequence-specific and cooperative binding of the drug. By using a 36 bp sequence
comprised of a repeating AGC motif immobilized on a planar gold surface, the release
was sustained for 12 days. However, the high curvature of AuNPs resulted in a much
more rapid release, emphasizing the importance of particle shape and curvature on the
structure of the DNA layer and subsequently the release of the drug. These results will
significantly impact the future design of therapeutic nanoparticles driven by the excellent
tailorability of nucleic acid nanomaterials. Future work will investigate the synergism of

118

oligonucleotide sequence, structure, and particle shape and their influence on drug release
profiles.
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Figure 6.1. Daunomycin loading as a function of molar ratio of drug to DNA. DNA
sequences were designed to have either 12, 24, or 36 bp binding regions corresponding to
4X (), 8X (), or 12X () binding sites. Both RAN and AGC sequences loaded
comparable amounts of daunomycin. Results are shown as average of both sequences.
Loading values approached theoretical maxima for all sequences at a molar ratio of 500:1
drug:DNA.

120

Figure 6.2. Comparing drug release between RAN sequences with 4X, 8X, and 12X
intercalation sites. RAN sequences pre-loaded with drug were self-assembled on a planar
gold surface and submerged in PBS at 37oC. Sequence lengths of 4X (), 8X (), or
12X () were investigated. Drug release from RAN is extended as the sequence length
increases, emphasizing monomer size-dependent release kinetics. Dotted lines represent a
fit of the first 60% of drug release to the Korsmeyer-Peppas equation.
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Figure 6.3. Comparing drug release between AGC sequences with 4X, 8X, and 12X
intercalation sites. AGC sequences pre-loaded with drug were self-assembled on a planar
gold surface and submerged in PBS at 37oC. Sequence lengths of 4X (), 8X (), or
12X () were investigated. Drug release from AGC is extended as the sequence length
increases, emphasizing monomer size-dependent release kinetics. Additionally, release is
extended at a greater rate compared to RAN, reinforcing the sequence-dependent release.
AGC 12X shows near zero-order release kinetics, indicating exquisite control of drug
transport. Dotted lines represent a fit of the first 60% of drug release to the KorsmeyerPeppas equation.
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Figure 6.4. Comparing release rate constants (kKP) of RAN and AGC sequences at
increasing sequence lengths. Sequence designators of 4X, 8X, and 12X represent the
theoretical and observed loading of daunomycin per oligonucleotide. For RAN (), kKP
has a negative linear correlation to sequence length. For AGC (), all values of kKP are
lower than that of RAN with equivalent length. Additionally, across the same length
scales, kKP for AGC decreases according to a power law relationship.
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Figure 6.5. Comparing drug release between 15 nm AuNPs conjugated with RAN and
AGC sequences with 12X intercalation sites. Release from AuNPs is unique due to the
high surface curvature of the particles compared to planar gold. Both sequences release
drug at a much more rapid rate in comparison. Here, the sequence specificity is still
showcased as AuNP-AGC () release at a slower rate compared to AuNP-RAN ().
Both release profiles fit well with first-order release kinetics, corresponding to n = 0.43 as
determined via fitting to the Korsmeyer-Peppas equation.
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Table 6.1
DNA Sequences
Name

Sequence

RAN (4X)

5’–S-TTTTATGGTTTACAATATT
CCAAATGTTATAA

RAN (8X)

5’–S-TTTTATGGTTTACAATATTGTTTACAATATT
CCAAATGTTATAACAAATGTTATAA

RAN (12X)

5’–S-TTTTATGGTTTACAATATTGTTTACAATATTGTTTACAATATT
CCAAATGTTATAACAAATGTTATAACAAATGTTATAA

AGC (4X)

5’–S-TTTTATACGACGACGACGA
TGCTGCTGCTGCT

AGC (8X)

5’–S-TTTTATAGCAGCAGCAGCAGCAGCAGCAGCA
TCGTCGTCGTCGTCGTCGTCGTCGT

AGC (12X)

5’–S-TTTTATAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA
TCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGT
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Table 6.2
Release Rate Constants

RAN

AGC

AuNP

kKP

n

R2

4X

0.136

0.572

0.972

8X

0.096

0.524

0.959

12X

0.049

0.606

0.987

4X

0.061

0.636

0.982

8X

0.010

0.864

0.993

12X

0.004

0.976

0.998

RAN 12X

0.401

0.43

0.950

AGC 12X

0.304

0.43

0.939
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Chapter 7
Conclusions
7.1 Significance
In the battle against cancer, much progress has been made in the past century.
However, the fight is far from over. During the COVID-19 pandemic, the suggestion
from professional societies such as the American Cancer Society, the American Society
of Clinical Oncology, the American Society of Breast Surgeons, the American College
of Radiology, and the American Society for Colposcopy and Cervical Pathology was to
postpone routine healthcare checkups in order to avoid possible exposure to the virus;
this included routine cancer screenings.319 As a result, many screenings for common
cancers such as breast, cervical, and colorectal were skipped over the past two years.
Therefore, the incidence of cancer in the future is expected to trend upward.
Nanomedicine has seen an unprecedented expansion in recent years for the
diagnosis and treatment of cancer. The profound tunability of nanomaterials and the
capability to bind, adsorb, or carry drugs make them extremely attractive in the field of
oncology and has had significant impact on the field.320 Of the multitude of materials at
our disposal, nucleic acids present the most compelling choice for bottom-up assembly of
anticancer nanomedicines. Unfortunately, to date there has been a significant lack of
methods to control the release of drugs from nucleic acid nanocarriers for sustained drug
release. With this dissertation, novel biomimetic strategies for controlling drug release
are exhibited via facile manipulation of immobilized DNA nanoarchitectures using both
surface-bound and intercalating drugs. Using a high-affinity binding sequence for
daunomycin and increasing the thickness of the DNA layer, near zero-order release
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kinetics were observed, an unprecedented feat in the field. Thus, the strategies herein will
profoundly impact the field regarding the design of next-generation therapeutic
nanocarriers.
7.2 Broader Impacts
Spherical nucleic acids are not restricted to gold surfaces. Indeed, similar
structures have been formed on silica, iron oxide, proteins, liposomes, micelles, PLGA,
and as hollow spheres, and the oligonucleotide layer can be formed using DNA, RNA,
peptide NAs, etc. Thus, the possibilities of customization and personalization are
extensive. Additionally, NA nanoparticles can formulated for more advanced delivery
systems such as inhalable therapeutics,321 blood-brain-barrier penetration,322 and
injectable hydrogels,323 exemplifying their applicability in a number of unique situations.
Furthermore, in this work, two specific template drugs were utilized. Dexamethasone was
bound to the gold surface via electrostatic attraction from the fluorine atom; thus, other
fluorinated corticosteroids, or other small molecule drugs capable of sticking to gold, can
likely be utilized in the same manner for controlled drug release. Similarly, daunomycin
is not the only intercalating therapeutic, and indeed many therapeutics interact with the
major and minor grooves of nucleic acids in different ways - such drugs can be
investigated for sequence specificity and exploited in similar ways to control drug
release. Therefore, the methods of drug release described in this work can be exploited in
a vast number of distinct ways in order to produce highly tailorable and personalizable
nanocarriers for drug delivery in the treatment of many pressing diseases.
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7.3 Concluding Remarks
The main conclusions of this work are as follows: 1) the nanoarchitectures of
nucleic acid monolayers on gold surfaces can be manipulated via sequence and length
selection, cation addition, immobilization strategy, and core surface curvature, 2) the
release of a surface-bound drug can be controlled by inducing distinct nanoarchitecture,
e.g., folded or upright nucleic acid orientations, and 3) the release of an intercalating drug
can be controlled via sequence selection, changes in layer thickness, and core surface
curvature. These strategies will have a great impact on future design of next-generation
therapeutic nanocarriers and will improve personalized therapies for chemotherapeutic
delivery.
The influence of surface curvature presents one of the most interesting
possibilities. Future work should involve drug release from polyhedral, discoidal, or rodshaped gold nanoparticles to determine how curvature and surface area affect the release
rate. In Chapter 2, the influence of nanoparticle shape was discussed in terms of transport
through physiological barriers. Thus, a more focused investigation of how these
properties influence drug release is needed.
Additionally, a clinically focused nanocarrier will gain significant advantages
using a targeting ligand. Nucleic acid aptamers constitute the likely next-generation of
targeting molecules, although they have not been optimized for clinical use as of yet.
Oligonucleotide-conjugated antibodies are another advanced method of targeting,
provided that their addition does not significantly later the size or shape of the underlying
nanocarrier. These molecules can be conjugated to the surface of NA nanocarriers either
via complementary hybridization or through the use of a long PEG spacer, which is
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charge neutral and thus able to penetrate dense NA layers on gold surfaces. Thus, through
utilization of the techniques discovered herein to control drug release, novel nanocarriers
can be synthesized with different shapes and sizes (determined by core structure) and
different targeting capabilities (determined by the outer layer structure), with controllable
drug release NA layers remaining on the core surface.
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